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INTRODUCTION 
Coupling of liquid chromatography (LC) and mass spectrometry (MS) has 
given a powerful and selective analytical tool for various applications ranging 
from routine monitoring of contaminants in environmental samples to the 
identification of novel synthesis products. This coupling became possible due to 
the invention of electrospray ionisation source. Liquid chromatography/mass 
spectrometry (LC/MS) has ever since developed rapidly, both in LC part and MS 
part. An important component from the sensitivity perspective is the ionisation 
source of MS, which is generating ions from the LC effluent. Ionisation is 
affected by many different factors, such as the properties of analytes, matrix 
components, source parameters, eluent composition etc. One way for obtaining 
the best results is having several different sources operating with different 
principles and choosing the optimal source for a specific analysis. Today there are 
many novel ion sources introduced in the literature and several of them are also 
available commercially. In order for analyst to be able to choose among them, a 
lot of work needs to be done to compare different sources. 
Electrospray ionisation (ESI) source is most used source for generating ions in 
MS. Some other popular sources are atmospheric pressure chemical ionisation 
(APCI) and atmospheric pressure photoionisation (APPI) sources. While they 
enable analysis of many different compounds, none of these sources is universal. 
Several novel sources are designed to give even better performance by lowering 
limits of detection and reducing matrix effects, such as heated ESI (HESI) 
sources, and to be able to analyse wider range of analytes, such as multimode 
(MMI) sources, which combine different ionisation modes in one source. 
A novel nebuliser developed in our group for ESI has been characterised in 
this study as part of an effort to further enhance the ESI method (Paper I). Its 
novelty resides in the addition of nebuliser gas capillary inside the liquid capil-
lary. This enhances the nebulisation process by generating finer droplets of 
effluent. However it needed optimisation and comparison with other sources. 
During the thesis studies another possibility for enhancement of LC/MS 
method was researched: monolithic chromatographic columns (Papers IV–VI). 
Since monolithic columns are not as accessible as ionisation sources, we discuss 
the effect of ionisation sources in detail. 
The aim of the thesis was two-fold: the comparison of different ionisation 
methods and secondly the optimisation of novel nebuliser. Also one of the aims was 
to compare the optimised novel ESI nebuliser with commercially available ESI 
nebuliser, in order to see which one has advantage in practical analysis (Paper II). 
Different ionisation sources were compared to the performance of conven-
tional ESI source under practical analysis conditions (Paper III). The comparison 
was performed on the basis of analysis of pesticides commonly analysed with 
LC/MS and having highly varying properties from the point of view of 
ionisation and compared with relevant statistical tests. It was also important to 
fulfil the aims of this work in the context of practical samples, such as garlic, 
honey, tomato etc., using relevant analytes (pesticides, drugs). 
12 
1. REVIEW OF LITERATURE 
1.1. Liquid chromatography/mass spectrometry 
LC/MS is widely used method for the determination of many different analytes, 
such as pesticides,1–4 lipids,5 amino acids,6 pharmaceuticals,7 polymers and their 
additives,8,9 metabolites, etc.10 in different matrices such as fruits and vege-
tables,2 blood plasma,1,5 bees,11,12 human body fluids10 etc. LC/MS is very 
diverse in its instrumentation, employing different stationary phases, pressures 
(HPLC vs UHPLC) and eluents in the LC part as well as a number of ionisation 
sources13,14 (ESI, APCI, APPI, MALDI, EI etc.) and mass analysers (ion trap, 
triple quadrupole etc.) in the MS part. Since it has such a variety of instru-
mentation and its uses, there is a need to investigate the advantages and 
disadvantages of the different parts of LC/MS instrumentation and compare 
them with each other in order to find the best combinations for different 
applications. This study focuses on the MS ionisation sources part of LC/MS in 
order to choose between different sources on the basis of their advantages and 
disadvantages. 
 
 
1.2. Ionisation sources in LC/MS 
Since the introduction of electrospray ionisation (ESI) source by Dole et al.15 
and Fenn et al.16 several new ionisation sources for generating gas phase ions 
from solution phase have been introduced and commercialised. The two main 
principles for atmospheric pressure ionisation (API) are based on liquid phase 
ionisation processes (ESI, HESI, DESI, EESI etc.) or gas phase ionisation 
processes (APCI, APPI).  
The most popular sources in addition to ESI are the atmospheric pressure 
chemical ionisation (APCI)13,17 and atmospheric pressure photoionisation 
(APPI) sources, which can be seen as adaption of the APCI concept.18 Some of 
the new developments have offered additional capabilities to the 2 main ionisa-
tion processes. Heated electrospray ionisation (HESI) is a modification of the 
ESI source with additional sheath gas to further assist the nebulisation of 
effluent.19,20 Among other new sources the multimode ionisation (MMI) source 
is of great interest.13 In the MMI source the advantages of different ionisation 
techniques are combined such as ESI-APCI,21–23 ESI-APPI23 or APCI-APPI.24 
With MMI it is possible to analyse a wider range of analytes with different 
hydrophobicity, polarity, volatility, etc. than with the individual sources.25 
With increasing number of ion sources available it is of growing interest for 
researchers and chromatography practitioners to find the optimal ionisation 
source for a given LC/MS analysis task – one that gives highest sensitivity and 
lowest limits of detection, is least prone to matrix effects, etc. ESI is commonly 
seen as the default LC/MS ionisation source for analysing many different com-
pounds, but due to a number of recent developments in ionisation sources, it is 
13 
important to compare the performance of ESI source with the novel sources, to 
determine the most suitable ionisation mode for a given analytical task. 
 
 
1.2.1. ESI and HESI 
ESI is the most used ionisation source in coupling of LC with MS. ESI design is 
shown at Figure 1. The effluent coming from LC is sprayed into ionisation 
chamber by nebulising gas and generated ions are directed into MS entrance. 
ESI is usually considered more efficient for compounds that are ionised already 
in solution (i.e. have higher basicity) and, especially, if the formed ions have 
large hydrophobic moieties, that help the ionised compound to compete for the 
droplet surface, in order to escape to the gas phase.26 
HESI is similar to ESI ionisation source differing only by the addition of 
sheath gas flow around the spray nozzle to further enhance the desolvation of 
the effluent droplets (Figure 1), one such example is Agilent “Jet Stream” 
source used in this study. The sheath gas is super-heated nitrogen surrounding the 
nebulising gas capillary, forcing the nebulised droplet spray to form a narrower 
plume. This creates a more focused zone in the ionisation chamber for the 
generation of ions, increasing sensitivity and the ionisation efficiency, while 
potentially reducing matrix effects.20 HESI was introduced in 200920, therefore 
having far less published comparison material with other sources than ESI. HESI 
has been used, e.g., for the analysis of lipids in blood plasma,5 pesticides in 
grapefruit, orange, pear and sweet pepper,19 wide variety of pharmaceuticals,27 
steroidal lactones,28 glucuronide in bile29 and pteridines in insect pigments.30 
The ionisation process in electrospray-like ionisation sources is described 
mainly by two models: ion evaporation model (IEM) and charge residue model 
(CRM). In the spray plume the droplets will divide into smaller droplets via 
Coulomb fission. IEM proposes that when the droplets have shrunk to suffi-
ciently small size, the analyte ion can leave the droplet into the gas phase, thus 
replacing the Coulomb fission process. CRM, however, proposes that the droplet 
will divide into smaller droplets via Coulomb fission and the final droplet 
containing only one analyte molecule will decrease in size due to solvent 
evaporation, until there is only charged analyte ion remaining in gas 
phase.14,31,32 It is likely that both mechanisms occur depending on the analyte 
molecule. For smaller molecules IEM is shown to be more likely and for 
macromolecules CRM is the main mechanism.31 
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Figure 1. Instrumental principles of ESI and HESI. 
 
 
1.2.2. APCI and APPI 
In APCI and APPI the effluent is nebulised similarly as in ESI, but there is an 
additional heating to enhance the transition of analyte molecules to gas phase. 
The analyte is generally assumed to remain neutral in liquid phase and ioni-
sation is assumed to occur largely in gas phase, indirectly via corona needle in 
APCI or by UV-lamp in APPI. However, recent results33 cast some doubt on the 
assumption that APCI ionisation occurs only in the gas phase. It has been found 
that volatility is not required and that the parameters that govern ionisation in 
ESI and APCI sources are surprisingly similar. This implies that a combination 
of ionisation mechanisms might operate in the APCI source.33 However, based 
on 40 compounds and contrasting the large number of studies, where com-
pounds can be analysed with APCI but not with ESI, this similarity in ionisation 
parameters needs to be researched more closely in order to draw clearer conclu-
sions. Also it would be interesting to see if APPI exhibits the same behaviour in 
regard of ionisation efficiencies. It is largely accepted, that APPI and APCI are 
usually used for the analysis of more volatile and less polar compounds.13  
According to the traditional understanding in the case of APCI (Figure 2) the 
corona needle ionises first the nebulising gas and solvent molecules, that are 
present in large excess in the ionisation chamber. Subsequently the analyte 
molecules are ionised by the previously ionised gas and/or solvent molecules, 
thus the ionisation is determined by gas phase ion chemistry.9,13,34 
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Figure 2. Instrumental principles of APCI and APPI. 
 
APPI uses UV-lamp instead of corona needle for the ionisation (Figure 2). 
Since UV lamp does not necessarily need the molecule to reach it physically to 
ionise it, there is also a good probability that UV-lamp ionises the analyte 
directly. The ionisation mechanism of APPI follows similar mechanism as 
APCI, however the common gases (N2, O2) in the source are not ionised since 
they have higher ionisation energies (>12.6 eV) than the energy of the photons 
emitted from the commonly used krypton lamp (10.6 eV). Thus it is either solvent 
molecules, analyte molecules or molecules of added photoactive substances 
(dopants) that are ionised via ultraviolet light. The subsequent ionisation of 
analyte molecule depend on ionisation energies and proton affinities of analyte 
and other participating molecules. A dopant is usually used in order to enhance 
the ionisation efficiency of analyte in APPI. Dopant addition serves the purpose 
of generating more primary ions which can then ionise the analyte 
molecules.25,35 Different compounds have been used as a dopant (e.g. acetone, 
anisole, tetrahydrofuran, benzene), but toluene is most commonly used, for it 
has proven to be the most robust dopant.25,36 
 
 
1.2.3. Multimode sources 
The combination of different ionisation sources may offer combined advantages 
over the use of the respective sources separately.25 The principle of multimode 
ionisation source is shown in Figure 3 with the example of ESI–APCI source. 
Multimode source relies on the theoretical advantage of using two separate 
ionisation mechanisms such as ESI and APCI to complement each other and 
thus may lead to higher sensitivities, reduced matrix effects and robustness with 
16 
different matrices, without the need of switching between ionisation sources.25 
There are many different combinations of multimode sources such as APCI–
APPI,24 ESI–APCI,21,22 etc. and each of these combinations needs to be studied 
separately, because the combined ionisation sources may complement each 
other, but may also inhibit the performance of each other. For example APPI 
and APCI are more similar in their operating principle than ESI and APCI and 
significant differences in the operation of respective multimode sources may 
arise. Interestingly, the ESI–APCI source has been shown to have higher 
sensitivity compared to the respective ionisation sources separately21 while 
APCI–APPI source has been shown to have lower signal intensities than the 
individual sources.24 
Several different multimode sources are in use, but the concept is still novel 
and a sufficient amount of data has not yet been collected for drawing general 
conclusions in comparison with other ionisation sources. 
 
 
Figure 3. Instrumental principles of ESI-APCI multimode source. 
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1.2.4. Other sources 
Many other ionisation sources exist, which differ from the previous ones, such 
as electron ionisation (EI), where gaseous neutral analyte molecules are ionised 
in collision with high-energy electrons in order to produce radical cations.37 EI 
produces a lot of fragments and is not suitable when molecular ions are desired. 
Traditionally EI has been the standard ion source in gas chromatography-mass 
spectrometry, but lately has found uses in coupling with LC also.38 A softer 
ionisation method compared to EI is the matrix-assisted laser desorption 
ionisation (MALDI), where the sample is mixed with organic matrix for 
assisting the desorption and is then irradiated with a short laser pulse to produce 
a plume of ionised analyte that is subsequently analysed by MS. MALDI has 
become an especially powerful imaging tool for tissues.39 However, the 
coupling of online LC with MALDI is problematic.40 
In desorption electrospray ionisation (DESI)41 a spray from ESI source is 
directed at the surface of solid sample, thus desorbing and ionising the analyte 
molecules from the surface. MS inlet is positioned at an angle of the bouncing 
droplets from the surface containing ionised analyte. This allows for direct 
analysis of analytes from surfaces. Extractive electrospray ionisation (EESI)42 is 
also a variant of ESI where the effluent containing neutral analyte is sprayed at 
an angle with another ESI nebuliser spraying a solvent solution. In collision of 
the two sprays the analyte molecules are ionised. EESI allows for direct analysis 
of liquid matrices such as water and urine. DESI and EESI, as variants of ESI, 
can also be used for the analysis of wide variety of analytes.  
These are only a selection of the vast number of available ionisation sources. 
There is a lot more diversity and variations within each ionisation method and 
also with combinations of different sources.37 
 
 
1.3. Advantages and limitations of different sources 
Mostly the traditional ESI source has been compared with APCI and/or APPI 
sources. HESI and MMI ionisation sources have received much less attention, 
partly because they are novel sources. The most important comparison para-
meters have been the limit of detection (LoD),7,8,43–57 signal-to-noise ratio 
(S/N)7,48,50,53,56,58 and matrix effects (ME).19,46–48,50,55,56,59–61 Linearity47,48,53,56,57 
and sensitivity (as calibration graph slope)44,48,51,53 have also been considered. 
The results published in the literature agree only in very general terms. Signi-
ficant differences are evident in more specific aspects. The results are affected 
by the analytes used, matrix, solvent composition, ionisation source parameters, 
chromatographic separation etc.31 
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1.3.1. Linearity 
Linear range can be an important characteristic in comparison of different 
ionisation sources. For the analysis of estradiol ESI, APCI and APPI have been 
used, both in negative and positive mode. ESI in positive mode yielded 
narrower linear range than APCI or APPI. For negative mode the linear ranges 
for ESI, APCI and APPI were comparable.48 Cai and Syage53 compared ESI, 
APCI and APPI in positive mode and also found the narrowest linear range for 
the ESI source. Titato et al.57 found comparable linear ranges for pesticides in 
comparison of ESI with APCI. 
 
 
1.3.2. Matrix effects 
One crucial parameter of an ionisation source is the matrix effect – ionisation 
suppression or enhancement caused by co-eluting matrix components. Matrix 
effect results usually in decreased (less often enhanced) analyte signal therefore 
causing underestimation (less often overestimation) of analyte quantity in the 
sample. Matrix effect can be influenced by the matrix type, chemical properties 
of the analyte, sample pretreatment, separation, instrumentation used etc.62–64 
Therefore matrix effect can be very troublesome to eliminate. It would be 
preferable to use an ionisation source that is less prone to matrix effect. There-
fore this parameter has been often used for comparison of ionisation sources. 
APCI and APPI have been often compared to ESI in terms of matrix effect. In 
general more matrix effect has been observed for ESI,46,48,56,59–61 however, in 
some cases ESI has performed better than APCI or APPI.47,50,55 For example 
Hanold et al.65 observed that APPI was much less susceptible to ion suppression 
than ESI and APCI. The differences in the extent of matrix effect have been 
related to the different ionisation mechanisms of ESI and APCI/APPI,62 but as 
the factors contributing to matrix effect are diverse, the conflicting results in the 
literature are not surprising. Also variations between different varieties of 
electrospray sources have been observed. Stahnke et al.19 have shown that ESI 
was less prone to matrix effects than HESI, although the opposite would be 
expected due to HESI’s improved ion desolvation and confinement of the spray 
by thermal gradient.20 
 
 
1.3.3. Limit of detection, signal-to-noise ratio and sensitivity 
LoD is among the most often used comparison parameters for ionisation 
sources. A number of authors have observed comparable or lower LoD values 
for ESI compared to APCI or APPI when analysing pharmaceuticals,50 
pesticides,44,47,56 anabolic steroids,45 phytoestrogens,51 triazines, phenylureas,46 
aflatoxin M156 and flavonoids.43 But the opposite has been observed for lipids,53 
sulfonate esters,49 polymer additives,8 estradiol48 and pyrene derivatives52. It can 
be concluded that ESI and APCI/APPI are compound-dependent, as Thurman 
19 
et al.44 also concluded in case of pesticides. Comparing the compounds in the 
previous studies reveals that finding compound-property dependence patterns is 
complicated. It does seem, however, that compounds lacking ionic functional 
groups are performing better in APCI or APPI, in agreement with the classical 
ionisation models. 
In several papers ionisation sources have been compared on the basis of S/N 
at a given concentration. S/N can be improved greatly if noise levels could be 
reduced, thus leading to potentially lower LoDs. Higher noise levels can origi-
nate from matrix components, solvent clusters and contaminants.66,67 Thus 
different ionisation sources can have significantly different S/N ratios, as also 
observed in literature. It has usually been observed that APCI gives higher S/N 
values than ESI48,53 and APPI comparable or higher S/N values than 
APCI.7,48,53,58,65 However, Garcia-Ac et al.50 have shown the opposite: higher 
S/N for ESI than for APCI and APPI. 
Sensitivity can be measured as the calibration graph slope. Based on the data 
obtained by Keski-Rahkonen et al.48 and Cai and Syage53 it can be concluded 
that the best sensitivity in these studies was observed for APPI, followed by 
APCI. The lowest sensitivity was observed for ESI. A gain in analyte peak areas 
(up to 4 times) has been reported for HESI compared to ESI,5 therefore it can be 
expected that HESI should have at least comparable if not better sensitivity 
compared to conventional ESI. 
 
 
1.4. Novel developments in ESI sources 
There have been a number of novel developments for ESI sources. Some of the 
examples include modifying the nebuliser capillary tip68, implementing a wire 
into the liquid capillary69 and also the previously mentioned HESI with adding a 
super-heated desolvation gas capillary20, which has been commercialised by 
Agilent and is called “Jet Stream” ESI source.  
Maxwell et al.68 showed that an asymmetrically cut ESI emitter tip offers 
increased sensitivity (approximately two times) compared to the conventional 
emitter tip geometry. Additionally, Reschke et al.69 compared emitters with 
different internal diameters (ID) in the range of 5 μm to 360 μm and found that 
larger ID results in higher signals even though the reverse is generally accepted 
from both theory and practice70. However, both of these studies were carried out 
for nano-ESI emitters and their conclusions cannot be automatically transferred 
to the pneumatically assisted nebulisers implemented in the conventional high 
flow rate ESI sources.  
Bajic et al.71 have described the addition of a wire (preferably from a 
conducting material) into the liquid capillary. According to the results presented 
in ref 71 this addition improves ESI sensitivity by up to 3 times (for Reserpine) 
depending on the flow rate of the liquid. The sensitivity improvement due to the 
additional wire may result from two factors. First, the additional wire reduces 
the effective cross-sectional area of the liquid capillary. Secondly, more surface 
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is available in the nebuliser tip where electrochemical reactions – producing 
charge excess for the droplets – can take place.  
Among other novel nebuliser designs we have recently introduced (Paper I) 
a novel concept of nebuliser design. An additional capillary – carrying the 
nebuliser gas – was installed inside the liquid capillary. The advantages of the 
prototype – lowering of LoD values by up to 250 times – were shown for four 
analytes even without optimisation of the nebuliser design.72 This nebuliser 
design is called 3R nebuliser. 
It has also been described in the literature64 that different analytes as well as 
standards and samples may have somewhat different optimal ionisation and mass-
spectrometer parameters. This indicates that samples with different complexity 
may result in somewhat different optima and also nebuliser design suitable for 
one analyte may be less beneficial for another analyte. Therefore it is very 
important to test the newly developed ESI nebuliser under different conditions 
(e.g. standards vs samples, different analytes). 
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2. EXPERIMENTAL 
2.1. Chemicals 
Standards of carbendazim (99.0%), thiabendazole (98.5%), pymetrozine (99.0%), 
thiamethoxam (99.0%), vamidothion (99.0%), methiocarb sulfoxide (96.0%), 
chloridazon (98.0%), imidacloprid (99.5%), acetamiprid (98.5%), methiocarb 
sulfone (99.0%), thiacloprid (98.0%), imazalil (97.5%), thiophanate-methyl 
(97.5%), metribuzin (99.0%), pyrimethanil (99.0%), fenpropimorph (97.0%), 
spiroxamine (97.5%), propoxur (99.5%), triasulfuron (97.5%), bupirimate 
(98.0%), paclobutrazol (98.5%), methiocarb (98.5%), azoxystrobin (99.5%), 
epoxiconazole (98.5%), myclobutanil (97.5%), fenhexamid (99.0%), fluquin-
conazole (98.5%), flusilazole (99.5%), mepanipyrim (99.0%), bitertanol (98.0%), 
propiconazole (97.5%), triazophos (81.0%), methoxychlor (98.5%), ditalimfos 
(99.5%), tebufenozide (99.0%), benalaxyl (99.5%), pyrazophos (97.0%), 
buprofezin (99.0%), indoxacarb (99.5%), trifloxystrobin (99.5%), quinoxyfen 
(99.0%), pirimiphos-ethyl (98.5%) and hexythiazox (99.3%) were obtained 
from Dr. Erhenstorfer (Augsburg, Germany). Acetonitrile (HPLC grade) for 
sample pretreatment and chromatographic separation was acquired from Sigma-
Aldrich (St. Louis, United States). Methanol (HPLC grade) for chromatographic 
separation was acquired from J. T. Baker (Deventer, Netherlands). Toluene 
(99.9%) was acquired from Sigma-Aldrich (St. Louis, United States). Ultra-pure 
water was obtained with a Millipore Milli-Q Advantage A10 setup (Millipore, 
USA). For sample pretreatment anhydrous MgSO4 (99.2%) and glacial acetic 
acid, for acidification of acetonitrile, were acquired from Lach-Ner (Neratovice, 
Czech Republic), NaCl and sodium acetate from Reakhim (Leningrad, former 
Soviet Union) and primary-secondary amine (PSA) sorbent from Supelco 
(Bellefonte, USA). The aqueous mobile phase component (0.1% formic acid) 
for UHPLC were prepared from formic acid (98.0%, Riedel-de Haёn, 
Switzerland) and dissolved in ultra-pure water. The buffer (pH = 2.8) for HPLC 
was prepared from formic acid,1 mM ammonium acetate (99.0%, Fluka Chemie 
AG, Buchs, Germany) dissolved in ultra-pure water. 
 
 
2.2. Instrumentation 
In Papers I and II measurements were performed on an Agilent Series 1100 
LC/MSD Trap XCT (Agilent Technologies, Santa-Clara, USA). The instrument 
was equipped with a binary pump, an autosampler and a thermostatted column 
compartment. The injection volume was 5 or 10 μL, depending on analysis. For 
the separation, a 250 mm long Zorbax Eclipse XDB-C18 column with an Eclipse 
XDB-C18 12.5 mm pre-column (both with an internal diameter of 4.6 mm and 
particle size of 5 μm) was used. The mass spectrometer uses a quadrupole ion trap 
mass analyser. For instrument control, an Agilent ChemStation for LC Rev. A. 
10.02 and MSD Trap Control version 5.2 were used. The ion transportation 
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parameters were optimised for each analyte at a chromatographic flow rate via 
MSD Trap Control software.64 All of the analyses were carried out in positive 
mode. The mass spectrometer was operated in the selected reaction monitoring 
mode (SRM). Full MS2 spectra were recorded.  
In this study the dimensions and parameters of the novel nebuliser developed 
in our group were optimised. The optimised novel nebuliser was compared with 
a commercial nebuliser (with also optimised parameters according to procedure 
described by Kruve et al.64). Observed MS2 were independent of the nebuliser 
used. 
In Paper I for the analysis of carbendazim, thiabendazole, imazalil and 
methiocarb72 gradient elution with methanol and buffer solution (pH = 2.8) was 
used. The linear gradient started at 20% methanol and was raised to 100% 
within 15 min, then the column was eluted for 7 min with methanol. After that 
the methanol content was lowered to 20% in 3 min. Stabilisation time of 7 min 
was used between injections. Eluent flow rate was 0.8 ml/min.  
In Paper II for the analysis of honey samples gradient elution (flow rate 
0.8 mL/min) was used with acetate buffer and methanol. The methanol 
percentage (v/v) was raised from 40 to 100% in 17 min, maintained at 100% for 
5 min and lowered back to 40% in 3 min. The stabilisation time between runs 
was 7 min. 
In Paper III, for the comparison of different ionisation modes, an Agilent 
6495 Triple Quad LC/MS/MS instrument (Agilent Technologies, Santa-Clara, 
USA) was used. The UHPLC instrument was Agilent Infinity 1290, equipped 
with binary pump, an autosampler, a thermostatted column compartment. An 
Agilent Zorbax RRHD SB-C18 2.1×50 mm column with 1.8 μm particles was 
used for analyte separation. The injection volume was 1 μl. The mass spectro-
meter uses a triple quadrupole mass analyser and has exchangeable ion sources. 
7 different ionisation modes were used: ESI source, HESI source, APPI source 
with and without dopant and MMI source with simultaneous ESI and APCI 
ionisation, as well as both ESI and APCI separately. In the context of this work 
the term ionisation mode means both different sources as well different 
ionisation approaches within the same source (APPI with and without dopant; 
MMI source with simultaneous ESI and APCI, as well as ESI and APCI sepa-
rately). For instrument control Agilent MassHunter Workstation version B.07.00 
was used. The fragmentation voltages were optimised using the MassHunter 
Optimizer software. Sequential injections were made while changing collision 
energy in steps to find the values where most intense fragments were formed. 
After automatic fragmentation optimisation it was confirmed and fine-tuned 
manually. Manufacturer’s default source parameters were used for the analysis 
in the case of all sources. 
In Paper III UHPLC analysis of 41 pesticides in the comparison of different 
ionisation modes gradient elution was used with formic acid aqueous solution 
and acetonitrile at 0.3 ml/min flow rate. Acetonitrile percentage (v/v) was raised 
from 10 to 100% in 6 min, maintained at 100% for 1 min and returned to 10% 
in 1 min. The stabilisation time between runs was 0.5 min. 
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For DA-APPI the dopant (toluene) was infused after column with infusion 
pump from KD Scientific (Holliston, United States). The flow rate of dopant 
was optimised within 0–1.75 ml/h range for all 41 pesticides. The lowest flow 
rate that gave the best peak areas for the largest number of compounds was 
chosen. 0.5 ml/h proved to be optimal for that. 
For sample pretreatment, a centrifuge (Centrifuge 5430R) and stirrer (Mix-
Mate from Eppendorf (Hamburg, Germany)) were used. 
 
 
2.3. Selectivity 
Fragmentation was used to ensure selectivity and 1–3 fragment ions were 
monitored, depending of the specific compound, instrument and analysis. The 
corresponding precursor ions and product ions with other parameters can be 
seen in Table 1 for Paper I and II, in Table A – 1 for 41 compounds used in 
Paper III and in Table A – 2 for optimisation experiments. 
 
Table 1. Fragmentation paths for compounds used in Paper I and II with retention 
times. 
Paper I Paper II 
Compound tR (min) 
Precur-
sor ion
Prod. 
ion Compound 
tR 
(min)
Precur-
sor ion Prod. ion 
carbendazim 8.3 192 160 thiamethoxam 5.5 314 210; 180 
thiodicarb 14.3 202 175 imidacloprid 6.7 256 209; 175 
imazalil 14.0 297 201 acetamiprid 7.7 223 126; 187 
methiocarb 16.4 226 169 thiacloprid 8.8 253 126; 186 
 
 
In Paper II for the analysis of honey samples, selectivity was ensured by moni-
toring two ion transitions. After finding positive samples, an additional third ion 
transition for confirmation was used. Samples where all three ions could not be 
detected, that is at least one was not detected, were assigned as negative. 
Additional confirmation of positive samples was achieved by monitoring the 
abundance ratio of the signals of two most intense fragment ions. The 
acceptable boundaries for the abundance ratio were calculated from 64 
calibration samples from eight days with a concentration range from LoD up to 
0.3 mg/kg. The acceptable ratio was found as the mean ratio ± two standard 
deviations of the ratio found in the calibration samples. Analysis of the positive 
samples was repeated with the same criteria.  
It is also interesting to note that in the case of thiamethoxam the observed 
fragment ions were different from those commonly reported in the literature 
(Figure 4). In the literature, the common fragments, corresponding to the thia-
methoxam molecular ion ([M+H]+), are 211 and 18173–75. In this work, thia-
methoxam was primarily observed as a Na+ adduct with fragments 210 and 180 
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and the [M+H]+ ion was much less intense. This Na+ adduct effect was studied 
with ion-trap and triple quadrupole (with MMI source) instruments. While on 
the triple quadrupole instrument, the [M+H]+ ion for thiamethoxam (with 
observed fragments 211, 181, 210 and 180) was more intense than [M+Na]+, the 
effect was the same as observed on the ion-trap instrument, that is with 
[M+Na]+ fragments 211 and 181 were absent and 210 and 180 were most 
intense. Thus, the observed fragments were suitable for detection of thia-
methoxam in case of neonicotinoid detection in honey samples. 
 
 
Figure 4. Proposed fragmentation scheme of thiamethoxam. The fragments marked 
with asterisk (*) are proposed to leave as radicals. 
 
 
2.4. Samples for Paper II 
The honey samples were collected between 2005 and 2013 and were provided 
from different sources, thus different storage conditions had been applied. The 
majority of honey samples, 141, were the same as used by Rebane and Herodes76, 
114 samples were obtained from the Estonian Environmental Research Centre 
(EERC) and 39 samples from Estonian beekeepers.  
Samples used by Rebane and Herodes76 were mostly stored at room tem-
perature since their collection in 2005–2010, samples from the EERC (2010–
2013) were kept in a dark room, designated only for honey samples with the 
temperature kept at 10–17 °C, honey sample collection was completed by one 
person from markets, stores and fairs in their original packages. After acquiring 
the samples directly from beekeepers in January 2014 (collected by beekeepers 
mostly in the summer of 2013, with some samples from 2011 and 2012), they 
were kept in a refrigerator at –20 °C. 
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2.5. Sample pretreatments 
2.5.1. QuEChERS in the comparison of nebulisers in Paper I 
15 ml of 1% acetic acid in acetonitrile, 6 g MgSO4 and 1.5 g anhydrous sodium 
acetate was added to 15 g of homogenised sample. Shaken vigorously for 1 min 
and centrifuged at 5000 rpm for 1 min. The extract was transferred to tube 
containing 50 mg PSA + 150 mg anhydrous MgSO4 per 1 ml of extract. It was 
shaken again and centrifuged at 5000 rpm for 1 min.77 
 
 
2.5.2. QuEChERS for honey samples pretreatment in Paper II 
For sample pretreatment, the modified QuEChERS method77 was used. 1 g of 
honey was dissolved in 10 ml of purified water and 10 ml of acetonitrile. 4 g of 
MgSO4 and 1 g of NaCl were added and shaken for 1 min, followed by centri-
fugation for 3 min at 4400 rpm. An acetonitrile fraction of 1 ml was pipetted 
into a 2 ml centrifuge tube with 150 mg of MgSO4 and 25 mg of PSA for clean-
up, followed by stirring for 1 min. Tubes were centrifuged for 1 min at 
5000 rpm and the supernatant was taken for analysis. For every honey sample, 
sample pretreatment was performed, followed by subsequent analysis on the 
same day. 
 
 
2.5.3. QuEChERS for garlic and tomato samples  
in comparison of ionisation modes in Paper III 
For sample pretreatment modified QuEChERS (Quick, Easy, Cheap, Effective, 
Rugged and Safe) method was used.78 15 ml of 1% acetic acid in acetonitrile 
was added to 15 g of tomato or 5 g of garlic homogenised sample. In the case of 
garlic, 10 ml of ultrapure water was also added, because the water content is 
much lower in garlic matrix. Subsequently 6 g of MgSO4 and 1.5 g of sodium 
acetate were added. The mixture was stirred and centrifuged for 7 min at 
5000 rpm. 3.33 ml of the acetonitrile fraction was pipetted into 15 ml centrifuge 
tube with 500 mg of MgSO4 and 170 mg of primary secondary amine (PSA) for 
clean-up, followed by stirring and centrifugation for 7 min at 5000 rpm. The 
supernatant was taken for analysis. Samples were analysed in both extract and 
clean-up steps for the calculation of matrix effects with spiking of the blank 
sample, blank extract and blank extract clean-up steps. 
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2.6. Data analysis in experiments 
2.6.1. Calculation of validation parameters 
Upper limit of linear range was evaluated via visual inspection of residuals 
graph. The lower limit of linear range was determined by relative residuals. The 
limit of relative residuals was set to 20% as suggested in the SANCO guidelines 
(SANCO/12571/2013).79 
LoD was determined either by S/N or by standard deviation of residuals. S/N 
was used for the preliminary characterisation of novel 3R nebuliser, because it 
is often used as one of the comparison parameters in case of novel develop-
ments in ion sources. In the S/N approach the lowest concentration that gave 
S/N value of at least 3 was assigned as LoD. In the residuals approach the LoD 
was calculated according to the ICH validation guidelines:80,81 
 
LoD = 3.3 × ݏݐܽ݊݀ܽݎ݀ ݀݁ݒ݅ܽݐ݅݋݊ ݋݂ ݎ݁ݏ݅݀ݑ݈ܽݏݏ݈݋݌݁  (1) 
 
Both standard deviation of residuals and slope were determined in the LoD 
region, covering concentrations over approximately an order of magnitude. If it 
was not possible to confirm the calculated LoD with another fragment ion, then 
the lowest concentration where the peak of confirmatory ion was seen, was 
taken as LoD. The LoQ was determined by  
 
LoQ = 10 × ݏݐܽ݊݀ܽݎ݀ ݀݁ݒ݅ܽݐ݅݋݊ ݋݂ ݎ݁ݏ݅݀ݑ݈ܽݏݏ݈݋݌݁ . (2) 
 
S/N values from triple quadrupole mass spectrometer were obtained with the 
MassHunter software with signal definition as area and noise definition as 
Auto-RMS (root-mean-square of the baseline over time window). S/N values 
from ion-trap mass spectrometer for the comparison of nebulisers were obtained 
with Data Analysis software version 5.2, which calculates noise over the whole 
chromatogram except the peaks. 
Sensitivities of the ion sources were compared on the basis of calibration 
graph slopes in the linear range. As the slope values ranged over several orders 
of magnitude ratios of slopes were compared instead. 
For the comparison of sensitivity, S/N and LoD values, geometric mean (GM) 
as well as geometric standard deviation (sg) were used according to formulas,  
 
GM = ඥܽଵ × ܽଶ × ⋯ ܽ୬౤  (3) 
 
where an is the compound-wise ratio value of sensitivity, S/N or LoD values 
between two ionisation modes and n is the sum of all product ions over the 41 
compounds detected. Formula for geometric standard deviation is defined as 
follows, 
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where n is the same as in GM formula, ai is the same as an in GM formula, μg is 
the geometric mean of the ratio values of sensitivity, S/N or LoD values 
between two ionisation modes. The comparison of geometric means of the LoD, 
S/N and sensitivity ratios was done with HESI, because it gave the best results 
for these 3 parameters. 
Matrix effect was calculated as follows: 
 
ME = ܿ(୤୭୳୬ୢ)ܿ(ୱ୮୧୩ୣୢ) × 100% (5) 
 
where c(found) is the analyte concentration calculated from the analysis results 
and c(spiked) is the theoretical analyte concentration in the spiked sample. Matrix 
effect determinations were performed over a time period of 6 months in 4 dif-
ferent series. Within series the extraction step of the sample pretreatment was 
performed with blank samples and 3 replicates of spiked matrix samples. Part of 
the blank extract was spiked and samples for analysis were taken from each 
solution in this step. The sample clean-up step was then performed with the 3 
spiked matrix samples, blank extract and 3 replicates of the spiked extract. After 
the clean-up the blank sample was spiked and again samples for analysis were 
taken from each solution. Analysis of the samples was done in duplicate. 
In Paper III for repeatability determination 9 replicates in garlic matrix were 
used. Repeatabilities obtained with the different ionisation sources were com-
pared using the F-test and relative standard deviation of the signals of spiked 
garlic extracts (see Table A – 5). At first the statistical differences in variances 
of signals were established with comparison of the best performing source (ESI) 
with others using the F-test. Then the relative standard deviation was used to 
estimate if the statistical difference is of practical significance. If the relative 
standard deviation was over 10% for the source with higher repeatability stan-
dard deviation, then the difference was considered significant in practice. 
ANOVA, GLM and PCA analysis, as well as preparation of figures was per-
formed with the R free software environment for statistical computing and 
graphics version 3.2.0 with packages pca3d and rgl (for PCA). Data were scaled 
and centred before analysis. 
 
 
2.6.2. Proportions analysis 
In Paper II neonicotinoids in honey samples were analysed for the comparison 
of novel nebuliser with commercial nebuliser. Honey samples were acquired 
from different years and for positive honey samples confidence intervals (the 
borders where in case of normal distribution the true value of the observed 
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parameter is with given condifence probability) were calculated. Proportions 
with 95% confidence intervals were calculated on a year-wise basis using the 
following formula: 
 
݌ = ݊୮୭ୱ + 2݊ + 4 ; ܹ = 2 × ඨ
݌(1 − ݌)
݊ + 4  (6) 
 
where p is proportion, npos is the number of positive samples, n is the overall 
number of samples and W is the error margin at a 95% confidence level.82 
 
 
2.6.3. Principal component analysis (PCA) 
In Paper III PCA was performed for analytes with molecular parameters: 
retention time (tR), acidity of the conjugate acid (i.e. pKa of protonated analyte), 
octanol-water partition coefficient (logPo/w), molecular weight (MW) (values 
and additional information in Table A – 4) and separately for LoD and matrix 
effect data.  
Three principal components were used for the analysis of molecular para-
meters, describing 97% of variance in data. Then the data points on the 3D plot 
of the 4 molecular parameters were analysed in the context of LoD and ME 
values. Separately for each ionisation mode the LoD and ME values were 
divided into 4 groups of equal size, where each group had 25% of the data 
points. Then the PCA plot was analysed in order to see if the LoD and ME 
values were in an observable correlation with the PCA.  
Another PCA was done to compare ionisation modes using only LoD or ME 
data, in order to see the profile differences of the different ionisation modes. 
Three principal components were used for LoD and ME, describing 84% and 
67% of variance, respectively. 
If one point of data was missing for a compound the whole compound was 
omitted because of the requirement of PCA that the data matrix is complete. 
Thus, altogether 36 compounds were used for LoD and 40 compounds were 
used for ME profile analysis. In the analysis of LoD PCA plot myclobutanil was 
deliberately omitted from the dataset, because it had LoD results that were 
heavily influenced by existence and detection concentration levels of qualitative 
fragmentation ions. 
 
 
2.6.4. Full factorial design for the optimisation of 3R nebuliser 
Full factorial design83 was used to plan the nebuliser optimisation experiments 
for both pesticides (standard solution and spiked garlic sample, both 1 mg/kg) 
and pharmaceuticals. For specifying most crucial parameters a two level design 
was used for 5 parameters (for instrumentation details see Figure 11):  
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1.  Capillary B ID (B_ID): 0.25 mm and 0.50 mm;  
2.  Capillary C (C) presence: Yes (value 1 in GLM model) or No (value 0 in 
GLM model);  
3.  Capillary C ID (C_ID): 90 μm and 175 μm (corresponding OD were 230 and 
360 μm, therefore both could be implemented only if Capillary B ID was 
0.5 mm);  
4.  Capillary C pressure (Cp): if present: 8 bar and 14 bar; 
5.  Capillary A pressure (CA): 5 and 12 psi; 
6.  Capillary Voltage (CapV): 2500 V and 4000 V. 
 
The parameter levels were chosen according to both previous experiences and 
to cover a wide range of possible parameter values (for gas pressures and 
capillary voltages). For example the approximate dimensions of commercial 
ESI nebuliser are 150 μm ID and 250 μm OD for liquid capillary, 575 μm ID 
and 1700 μm OD for gas capillary. 
Due to the technical reasons – mainly the limited long-term stability of the 
MS and the analytes – it was impossible to include more parameter levels into 
the parameter effect study, though more information on the nebulisation mecha-
nism could be gathered this way. In order to detect parameters significantly 
influencing the ESI/MS sensitivity a two level data analysis was performed. 
First, the parameters statistically significantly influencing the ESI/MS signal 
were detected with ANOVA. Thereafter, the parameters, previously found to be 
statistically significant, were implemented into a GLM. GLM was used to 
estimate the physical impact (how large signal increase/decrease occurs due to a 
change of a parameter value) of each parameter and all possible two-parameter 
interactions. This two-stage data treatment is necessary as some parameters 
being statistically significant may have considerably lower influence on the 
ESI/MS signal than other parameters also being statistically significant. Before 
data treatment both parameter levels and obtained peak areas were scaled in 
order to obtain comparable results. The GLM model was obtained in the form: 
 
ܣ݈݊ܽݕݐ݁ ݈ܵ݅݃݊ܽ = ∑ ܿ݋݁ ୧݂ × ݌ܽݎܽ݉݁ݐ݁ݎ୧଺௜ + ଵଶ ∑ ∑ ܿ݋݁ ୩݂୪ × ݅݊ݐ݁ݎܽܿݐ݅݋݊୩୪଺௟଺௞   (7) 
 
where only two parameter interactions were considered as follows: 
 
݅݊ݐ݁ݎܽܿݐ݅݋݊୩୪ = ݌ܽݎܽ݉݁ݐ݁ݎ୩ × ݌ܽݎܽ݉݁ݐ݁ݎ୪ (8) 
 
The aim of the GLM model is not a full and accurate description of the electro-
spray ionisation process, but revealing nebuliser design elements and working 
parameters that have significant impact on ESI/MS signal. The impact of each 
parameter or parameter interaction can be estimated from the absolute value of 
the coefficients – the larger the absolute coefficient the larger is the impact of 
the parameter-parameter interaction. 
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2.7. Design of experiment for ionisation modes 
comparison 
A high concentration was selected for matrix effect and repeatability de-
termination in order to avoid the loss of signal due to ionisation suppression 
with sources that give higher LoD values. This concentration was mostly at the 
upper part or near the upper limit of linear ranges, corresponding to the 
concentration range where the maximum residue limits (MRLs) of most of the 
compounds are in garlic and tomato (0.01–0.5 mg/kg). The concentration in 
matrices was approximately 0.1 mg/kg in garlic and in tomato. The corres-
ponding solvent concentrations of the pesticides in the analysed samples were 
approximately 0.05 mg/kg and 0.16 mg/kg. 
Manufacturers’ default source parameters were used for all ionisation 
sources. It was impractical to use individual source parameters for each 
compound in a study like this, as the gas flow rates and temperatures take a lot 
of time for stabilisation and therefore cannot be reasonably varied within a run. 
Additionally, different solvent compositions are expected to have somewhat 
different optimal source parameters. At the same time this study includes a large 
number of analytes, with very different retention times, and therefore eluting in 
very different solvent compositions. The average optimal parameter set is 
therefore expected not to deviate significantly from the default values. 
SRM was used instead of full scan mode. For the absolute comparison of 
ionisation efficiencies in the sources full scan monitoring would be more 
proper. However, full scan would be impractical (especially keeping in mind 
selectivity), since SRM is mainly used in regular analysis of complex samples 
in order to ensure selectivity. 
Besides the ionisation mode the results depend on compounds and elution 
conditions as well as on the MS system and ion source design and in order to 
obtain general conclusions these need to be cancelled out or accounted for. The 
compound dependence is accounted for by including compounds with varying 
properties. Dependence on the elution conditions and MS system is cancelled 
out by using all the MS sources on the same MS and with the same chromato-
graphic method. 
Dependence on the ion source design cannot be directly addressed in this 
experimental design, so that rigorously speaking, the results are applicable only 
to the sources used in this work. However, it has been demonstrated recently84 
that the relative order of the compounds by ionisation efficiency largely follow 
the same trend across different mass analysers, indicating that the main 
processes responsible for ionisation are the same in different instruments 
regardless of different source design. Also, since all manufacturers of ion 
sources adhere to the same general goals – trying to produce as robust and sen-
sitive ion sources as possible – it is expected that the general conclusions are 
valid for the same source types from different manufacturers. 
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3. RESULTS AND DISCUSSION 
3.1. Comparison of ionisation sources 
Due to the large amount of different ionisation sources and the constant 
development of novel sources, it is important to compare different sources in 
order to find the optimal source for different applications. The aim of the 
comparison of different ionisation modes was to determine the ionisation source 
providing highest sensitivity and robustness for the analysis of pesticides. 
Thurman et al.44 showed that for different pesticide classes different ionisation 
sources (ESI or APCI) were optimal. Therefore it is interesting to see if the 
novel MMI source offers useful properties of combined sources and therefore 
minimising the need to use different sources. 7 different ionisation modes – 
ESI, HESI, direct APPI, DA-APPI and MMI with ESI and APCI mode 
simultaneously and separately, were used for the analysis of pesticides in 
tomato and garlic. 
Pesticides are widely used for crop protection and the large number of 
different pesticides demands strict control over the MRLs established by EU 
and other authorised organisations3,85,86. Pesticides differ widely by polarity, 
acid/base properties, hydrophobicity etc. thus several ionisation sources have 
been used for their analysis including ESI, APCI and HESI19,44,47,86.  
 
 
3.1.1. Comparison of chromatogram profiles 
The peak profiles of different ionisation modes can give useful information 
about the general picture of ionisation efficiencies. As can be seen in Figure 5 
relative peak areas of the compounds depend strongly on ionisation mode. For 
example, pirimiphos-ethyl gives large peaks in HESI and ESI modes (orange 
peak at 5.9 min in Figure 5), while for other ionisation modes the peak area of 
pirimiphos-ethyl is comparable to other compounds. Also much smaller (or 
absent) peaks of MMI-APCI are noticeable compared with other ionisation 
modes at the same concentrations. It is interesting that for both APPI modes the 
peak areas of different compounds are much closer to each other than for other 
ionisation modes (but at the same time, generally lower than with other modes). 
From data in Figure 5 both APPI modes seem to be less discriminating between 
compounds based on peak areas.  
It has been shown that ionisation efficiency of compounds in ESI is affected 
by the ionisation in the solution phase and by competition for the surface of the 
droplets14,87. Recently it has been demonstrated that the relative order of com-
pounds in ionisation efficiency scales is similar between ESI and APCI33. From 
Figure 5 also the similar profiles of chromatograms obtained with ESI and 
APCI can be observed. However, the chromatograms in Figure 5 seem to show 
similar profiles of MMI-APCI with ESI and HESI, but MMI-ESI leads to a  
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Figure 5. Chromatograms of 41 pesticides with different ionization modes. Analytes 
were injected in acetonitrile at 0.01 mg/kg concentration. Note the different spans of the 
signal axis. 
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surprisingly different peak profile. The peak profiles of the 3 MMI modes are 
inconsistent across different data series acquired on different time, giving 
sometimes the profile of MMI-APCI in Figure 5 and sometimes the profile of 
MMI-ESI in Figure 5 for all 3 modes. It can be concluded that MMI source 
itself is not very robust in its performance between series. For other ionisation 
sources the profiles matched throughout the experiments carried out over a 
period of one year. 
A possible explanation for the less discriminating peak profiles of APPI is 
the direct ionisation mechanism. In the case of APPI the analyte molecule can 
be ionised both directly and indirectly.14,18,88 This potential reason needs to be 
researched more closely, in order to draw clearer conclusions. To the best of our 
knowledge there have been no studies relating the APPI ionisation efficiency 
with molecular parameters. 
 
 
3.1.2. Repeatability 
ESI and HESI displayed the best repeatability standard deviations pooled over 
all studied compounds: 3.1% and 3.4% respectively (Table A – 5), which can be 
considered acceptable. For both direct APPI and DA-APPI the average relative 
repeatability standard deviations were higher: 11.6% and 12.2%, respectively. 
The MMI ionisation modes display still worse repeatability: the average relative 
standard deviations were 18.3%, 34.3% and 23.0% for MMI, MMI-APCI and 
MMI-ESI, respectively, over the 41 compounds. The worst individual repeat-
abilities for ESI and HESI were 8.2% and 9.0%, for fenhezamid and 
tebufenozide, respectively. For direct APPI, DA-APPI, MMI, MMI-APCI and 
MMI-ESI the worst repeatabilities were 43.4% (methiocarb sulfone), 52.9% 
(ditalimfos), 37.8% (benalaxyl), 267.7% (pyrimethanil) and 38.4% (quinoxyfen), 
respectively. 
It needs to be considered that poor repeatability of an ionisation mode also 
influences determination of other parameters with the same ionisation mode 
(mainly with MMI ionisation modes), including matrix effect values. This can 
be seen in Figure 6, where matrix effect values are shown for 2 compounds. For 
mepanipyrim the repeatability with some ionisation modes is poor, thus leading 
to huge variability in signal enhancement and suppression. However, the goal 
was to get a general picture of the performances of different nebulisers, not the 
absolute values of ionisation suppression/enhancement, thus in spite of the high 
variability of matrix effects the obtained information is still useful for overall 
picture. 
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Figure 6. Example of matrix effect values over all series of data for chloridazon and 
mepanipyrim with all 7 ionization modes presented on a beeswarm plot. The high scatter 
of mepanipyrim matrix effect values in the case of MMI-APCI and MMI-ESI modes is 
caused by overall poor repeatability of mepanipyrim response with the MMI ion source. 
 
 
3.1.3. Matrix effects 
Matrix effect values were first analysed with t-test (95% confidence), com-
paring the values with 100%. If matrix effects were not present then no signifi-
cant difference from 100% should be observed over the data of 4 different series. 
Analysis showed that out of the 41 compounds there were no significant diffe-
rences from 100% for 9, 9, 18, 12, 7, 3 and 19 compounds in case of ESI, MMI, 
MMI-APCI, MMI-ESI, HESI, direct APPI and DA-APPI respectively in garlic 
and in tomato 36, 27, 16, 28, 36, 34 and 40 compounds in case of ESI, MMI, 
MMI-APCI, MMI-ESI, HESI, direct APPI and DA-APPI respectively. It can be 
seen that matrix effect values in case of MMI-APCI and DA-APPI were not 
significantly different for close to half of the compounds in garlic and for most 
of the compounds in case tomato (except MMI-APCI). The t-test results are 
influenced by both average matrix effect and the repeatability observed with the 
respective source. MMI-APCI showed high variability (see section 1.12.2) of 
the results, which therefore may mask some important deviations from 100%. 
Additionally statistical differences may be insignificant in practice. Thus matrix 
effect values were also compared with the limits (70–120%) established by the 
SANCO/12571/2013 guideline, which considers trueness (process efficiency) 
values between 70 and 120% as acceptable. Though process efficiency incor-
porates both matrix effect and recoveries from sample pretreatment, the matrix 
effect has to be at least in the same range to provide acceptable results. 
The results for garlic and tomato are shown in Figure 7. The data has been 
pooled over four independent data series (over 8000 datapoints) showing all 
individual datapoints. The same general picture was observed in all 4 data 
series, recorded during a time period of 6 months in the case of all three MMI 
ionisation modes, HESI, ESI and direct APPI and in 2 data series during one 
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month in the case of DA-APPI. Figure 7 reveals that all three MMI ionisation 
modes and HESI suffer from ionisation suppression or enhancement for a 
significant number of compounds (although, as mentioned above in a number of 
cases the poor repeatability can be the cause of large difference from 100%). 
HESI performs better than the three MMI ionisation modes but in the case of 
HESI there are still only 65% and 70% of the compounds (in garlic and tomato 
matrix, respectively) within the acceptable matrix effect limits as suggested by 
SANCO. These results for HESI are in agreement with those observed by 
Stahnke et al.19 Direct APPI has significant ionisation enhancement for garlic, 
with only 57% of the compounds within the limits, but shows better results for 
tomato, with 82% within limits. ESI and DA-APPI exhibit the least ionisation 
enhancement or suppression: 89% and 83% of the compounds, respectively, 
were within the acceptable limits in garlic and 93% and 91%, respectively, in 
tomato. It can be concluded that ESI and DA-APPI have least matrix effects in 
the case of tomato and garlic samples. 
As would be expected, all ionisation modes have stronger ionisation 
enhancement or suppression in garlic samples than in tomato samples. Garlic is 
considered one of the worst matrices from the LC/MS matrix effect perspective, 
whereas tomato is a relatively simple matrix.89 The three MMI ionisation modes 
and HESI still display significant ionisation suppression or enhancement in 
tomato matrix. Only direct APPI, DA-APPI and ESI have over 80% of the data 
points within the acceptable limits for tomato samples. 
The results on matrix effect published in literature are conflicting. Some studies 
show ESI to be less prone to matrix effect compared to APCI or APPI,46,48,56,59–61 
but other studies show the opposite.47,50,55 This is most probably due to the 
variability of compounds and matrices analysed and elution conditions used. 
Since APPI/APCI have different mechanisms of ionisation compared to ESI, it is 
not unexpected that depending on the analyte and the co-eluting matrix components 
the results may vary. Based on the results of this study it can be concluded that for a 
large variety of small neutral molecules (containing both nitrogen and oxygen 
bases with very different ionisation sites) ESI seems to have from the point of 
view of matrix effect advantage over APPI, 3 MMI modes and HESI. 
Comparing the ionisation modes compound-wise gave interesting results. 
Compounds that had statistically significant difference from 100% and gave 
consistently out of limits matrix effect values in all series after complete sample 
pretreatment were identified. Ionisation of pymetrozine was suppressed in all 4 
measurement series in all ionisation modes except for ESI (in garlic and tomato) 
and DA-APPI (in tomato). The most probable reason is that pymetrozine is the 
first eluting compound with retention time tR = 0.57 min (dead time 0.50 min), 
while all other compounds have retention time over 1.7 minutes. With this 
retention time pymetrozine co-elutes with early-eluting matrix components as 
well as possible salt residues from the sample pretreatment. In spite of this the 
matrix effect of pymetrozine in the ESI source is within the acceptable limits 
even under such conditions. 
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Figure 7. Matrix effects in garlic and tomato for different ionization sources. Lines at 
120% and 70% refer to the recommended limits suggested by SANCO. The data have 
been pooled over four independent data series and each point on figure marks one data-
point. 
 
From the obtained data it is possible to assess the ability of MMI to combine 
advantages of ESI and APCI ionisation. For MMI strong ionisation suppression 
or enhancement was observed for 5 compounds. To 4 out of these compounds 
suppression was observed either with MMI-APCI or with MMI-ESI and for one 
compound (pymetrozine) with both of these modes. Therefore to these 4 com-
pounds MMI fails to cope with matrix effect by having an alternative ionisation 
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mechanism. On the other hand for 7 compounds MMI-APCI produced strong 
ionisation suppression or enhancement and for 2 compounds strong ionisation 
suppression with MMI-ESI in garlic samples, but MMI did not show ionisation 
suppression or enhancement. Similar trends were also observed for tomato 
matrix. Therefore the advantages of MMI tend to be strongly compound-
dependent. Data in Figure 7 indicates that MMI is by matrix effect comparable 
with MMI-ESI and inferior to ESI, thus offering no real advantage. 
The general trend of the ionisation enhancement and suppression across the 
chromatogram reveals more ionisation suppression than enhancement in the 
first half of the chromatogram and more enhancement in the second half of the 
chromatogram for all three MMI modes. The observed ionisation suppression 
may be caused by polar or ionic compounds in the extract and eluting in the 
beginning of the chromatogram. No other significant trends were observed. 
PCA analysis of matrix effects within a series and also in the context of 
molecular parameters showed no correlations. That is to be expected, since 
matrix effect is also dependent on the matrix components and concentrations of 
the components among other variables. Thus it was not expected that ME could 
be explained by analytes molecular parameters alone. 
 
 
3.1.4. Linearity 
The linear ranges for ESI (Figure 8 and Table 2) are in general wide and extend 
to low concentrations. ESI is closely followed by HESI, DA-APPI and MMI. 
All three have on average narrower linear ranges than ESI. The MMI-ESI 
source has slightly wider linear ranges that extend to lower concentrations com-
pared to direct APPI and MMI-APCI ionisation modes. However, for MMI-ESI 
and especially for MMI-APCI the linear range for many compounds could not 
be determined, because for these compounds no linearity was observed (MMI-
ESI and MMI-APCI) or the number of data points with significant signal was 
too small for linearity determination (MMI-APCI). 
In the case of ESI the linear ranges could be determined for all compounds 
except for thiophanate-methyl (signals were obtained for concentrations range 
of less than 1 order of magnitude). Three compounds did not have a linear range 
with HESI, 2 compound with MMI, 24 with MMI-APCI, 10 with MMI-ESI, 7 
with APPI and 6 with DA-APPI, because there were either not enough points 
for the given compound or linearity was not observed in the analysed range. In 
the case of 8 compounds (fenhexamid, mepanipyrim, bitertanol, methoxychlor, 
ditalimfos, tebufenozide, benalaxyl and quinoxyfen) the linear ranges could not 
be determined neither with MMI-ESI nor with MMI-APCI, but could be 
determined in with MMI. For trifloxystrobin linear range could not be 
determined with any arrangement of the MMI source. 
When comparing the linear ranges compound-wise it was observed that ESI 
gave wider linear ranges for 68% of compounds compared to HESI, 72% 
compared with MMI, 94% compared with MMI-APCI, 84% compared with 
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MMI-ESI, 88% compared with direct APPI and for 60% of compounds with DA-
APPI. Compounds that gave no linear range for one of the modes were not 
included in the percentage calculation. For ESI the geometric mean improvement 
of linear range width compared to other ionisation modes were 1.4, 1.5, 1.7, 1.5, 
1.6 and 1.3 times for HESI, MMI, MMI-APCI, MMI-ESI, direct APPI and DA-
APPI, respectively and the largest increase in linear range with ESI source 
compound-wise was 4.5, 5.0, 3.0, 5.0, 3.3 and 3.3 times, respectively. The 
largest decrease in linear range with ESI was 1.7, 1.3, 1.0, 1.1, 1.3 and 1.7 times 
narrower, respectively. Comparing the lower limits of linear ranges gives 
important information on the performance of ionisation modes in terms of 
quantitation at low analyte levels. Out of the 41 compounds 11 compounds in 
case of HESI had linear range extended to lower concentrations than ESI 
source. For MMI, MMI-APCI, MMI-ESI, direct APPI and DA-APPI these 
numbers were 12, 0, 5, 1 and 7, respectively. 
It can be concluded that ESI has superior linear range, both in terms of width 
and lower limit of linear range, compared to HESI, MMI, MMI-APCI, MMI-
ESI, direct APPI and DA-APPI. These results are not fully in line with those 
found in literature,48,53 where ESI has generally not been excelling in terms of 
linearity. However it has to be kept in mind that the linear ranges are highly 
dependent on the compound analysed, as can be seen in Figure 8.  
 
 
Figure 8. Linear ranges of different ionization modes. Each line marks a linear range 
for one compound. Absent lines denote compounds for which linear range could not be 
determined with the given ionization mode. 
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3.1.5. Limit of detection, signal-to-noise ratio and sensitivity 
Sensitivity, S/N and LoD describe closely related performance abilities: to 
produce a large number of analyte ions (ionisation efficiency) and to produce as 
little noise as possible. These parameters were studied in acetonitrile as solvent, 
because the aim was to compare the performance of the different ionisation 
modes unaffected by matrix effects. From the results (Table 3 and raw data in 
Table A – 6 and Table A – 7) it can be seen that in terms of sensitivity, similarly 
to S/N, HESI source performs the best. HESI performance is closely followed 
by ESI. Also MMI and MMI-ESI show similar results, but have lower sensi-
tivity than ESI. MMI-APCI and both APPI setups are the least sensitive and 
have lowest S/N. As expected, DA-APPI gave higher sensitivity (3 times) than 
direct APPI. 
It is interesting to note that according to the LoD results (Table 3 and Figure 
9) ESI is on the average comparable to HESI, although the latter has by an order 
of magnitude better sensitivity (slopes). A possible interpretation is that HESI is 
more effective than ESI in ionising both the analyte, and the matrix components.67 
This leads to the increase of the signal, but also to the increase of (chemical) 
noise. As a result, the standard deviation of residuals at low concentrations 
increases and causes higher LoDs (see Equation 1). In Figure 9 in comparison 
with ESI and HESI, MMI-ESI, MMI and DA-APPI ionisation modes give 
significantly higher LoD values. The highest LoD values were found with MMI-
APCI and direct APPI and DA-APPI ionisation modes. In compound-wise 
comparison in Table 3 MMI-APCI and both APPI modes give the highest LoDs, 
which is in agreement with the general picture seen with S/N and sensitivity. 
For DA-APPI increase in sensitivity has been reported in the literature 
previously when analysing pharmaceuticals7 and flavonoids.43 In another study 
improvement of LoD was not observed when adding toluene as dopant when 
analysing polymer additives.8 In this study DA-APPI does not perform much 
better than direct APPI. This is somewhat surprising, because one would expect 
that dopant would enhance the ionisation of analyte and not affect the noise 
levels. This was not the case in this study. Although analyte ionisation was 
indeed enhanced, the noise levels were elevated also, cancelling out the gain of 
enhanced ionisation, resulting in comparable LoD values. 
Although in the literature ESI has been found to have lower S/N than APCI 
or APPI,48,53 this study and the one carried out by Garcia-Ac et al.50 demonstrate 
that ESI has higher S/N.  
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Table 3. Comparison of S/N, sensitivity and LoD. APPI denotes direct APPI and DA-
APPI denotes dopant assisted APPI in acetonitrile as solvent. Geometric means (GM) 
were calculated from respective parameters ratios of two ionisation sources with geo-
metric standard deviation (sg). 
S/N Sensitivity   LoD 
GM sg GM sg   GM sg 
HESI/ESI 3.2 2.3 11 1.7 ESI/HESI 1.1 2.2 
HESI/MMI 4.2 3.1 83 3.8 MMI/HESI 4.5 6.1 
HESI/MMI–APCI 11 4.5 378 2.8 MMI–APCI/HESI 40 7.9 
HESI/MMI–ESI 4.7 3.8 57 3.4 MMI–ESI/HESI 6.1 7.3 
HESI/APPI 16 5.2 362 3.1 APPI/HESI 33 4.5 
HESI/DA–APPI 22 6.1 104 2.7 DA–APPI/HESI 32 4.6 
 
Figure 9. Boxplots of LoDs for different ionisation modes. Measurements were carried 
out in acetonitrile as solvent. 
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3.1.6. Principal Component Analysis of LoD results 
PCA was used in order to gain better understanding on which properties facili-
tate low LoD values on one or another ionisation source. The LoD PCA plot for 
3 principal components explaining 84% of data variance is presented in Figure 
10. From the PCA plot the ionisation modes grouped into 3 distinct groups. 
First group shows that HESI and ESI have similar profiles, with the fluctuations 
in the LoD values follow similar logic (not the same values). The correlation of 
the LoD values of ESI and HESI was high (R2=0.87). APPI and DA-APPI also 
follow similar logic in LoD values and the 3 MMI modes form a third group. 
The correlation of the LoD values were not as high as ESI and HESI had 
shown: APPI and DA-APPI had R2=0.56 and others were even worse. These 
groups seem to be formed based on ionisation mechanisms. However, MMI-ESI 
would be expected to be more similar to ESI, but this is not the case. It seems 
that there is some other process affecting the 3 MMI modes that seems to be 
sufficiently different from the ESI ionisation mechanism. One of the reasons 
could be that MMI-ESI has distinctly different geometry than HESI and ESI. 
 
 
Figure 10. PCA plot for LoDs of different ionization modes. 84% of data variance is 
explained by first 3 principal components. 
 
PCA was also carried out on the basis of the molecular parameters shown in 
Table A – 4 in Appendices. It was attempted to group the data points on the 3D 
plot according to LoD results, i.e. the LoD results did not affect the plot. However 
there were no clear correlations between the molecular parameters and LoD 
results. It can be because too few compounds were analysed for such analysis. 
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3.1.7. Conclusions of comparison 
The ionisation mechanism in different ionisation modes is an active research 
field.14,31,35,63 Nevertheless, some general trends are evident. Interestingly, the 
MMI source underperformed in comparison to the traditional ESI, although in 
theory it should have performed better,21,25 because of the addition of APCI. It is 
the opinion of the authors that at least part of the reason is that the geometry of 
the MMI ionisation chamber is optimal neither for ESI nor for APCI. The 
nebuliser capillary tip of the MMI source is situated at a much larger distance 
from the MS inlet than in the conventional ESI source. Also there is a small 
separating wall perpendicular to MS inlet functioning as separator of the ESI 
and APCI regions in the source. Because of this separating wall some part of the 
nebulised effluent is directed further away from MS inlet, causing decreased 
sensitivities and increased LoDs. This design of the ionisation chamber can be 
the reason why MMI-ESI performs better than MMI-APCI when the respective 
traditional APCI has in some cases shown to perform better than traditional 
ESI.43–45,48,49,51,57 
The unexpected underperformance of HESI may also be caused by the 
source design. HESI uses additional sheath gas to confine the spray plume for 
enhanced desolvation of droplets.20 However, the addition of sheath gas seems 
to increase matrix effects both in this study and in the report by Stahnke et al.19 
HESI is significantly more prone to chemical noise, which is the generation of 
ions from matrix components other than the analyte.67 Thus the advantage in 
sensitivity, achieved by more efficient ionisation of the analyte is partially 
offset by the increase in chemical noise. 
The poor sensitivity and high LoD values of direct APPI can be explained by 
the compounds properties used for the comparison. Although the pesticides vary 
significantly in polarity (logP between –0.2 to 5), they are still small molecules 
having ionisable functional groups (all have at least one nitrogen or oxygen 
atom in molecule), thus the poor performance might be caused by the com-
pounds that are not APPI specific. DA-APPI showed a significant improvement 
compared with direct APPI in the case of matrix effects and linear range. 
However, as the overall conclusion, the sensitivity and LoD values of DA-APPI 
are still much inferior to ESI. 
 
 
3.2. Novel 3R nebuliser for ESI source 
Novel 3R nebuliser offers a new concept of the ESI source introduced by Kruve 
et al.72. While the commercial nebuliser has spraying gas around the effluent 
only, the novel nebuliser introduces additional gas inside the effluent as is 
shown in Figure 11. It is hypothesised that the inner nebuliser gas gives addi-
tional nebulising power to generate smaller droplets and enhanced ionisation of 
analytes. 
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Figure 11. The dimensions of optimized 3R nebuliser with optimal gas pressures used. 
 
 
3.3. 3R nebuliser optimisation 
In order to determine the influence of the nebuliser parameters (as opposed to 
the parameters of the MS itself) on the analyte signals it is important to know if 
the MS parameters (the ones that influence ion transport inside the MS) need to 
be optimised simultaneously with the nebuliser parameters or may be fixed. For 
establishing this, 5 analytes (3 pesticides, namely thiamethoxam, paclobutrazol, 
etofenprox and 2 pharmaceuticals, namely meropenem and ertapenem) were 
chosen randomly and MS parameters were optimised (according to the procedure 
described by Kruve et al.64) for different nebuliser designs – two different ID-s 
of capillary B, with and without Capillary C for 3R nebuliser and a commercial 
nebuliser (altogether 5 different nebuliser designs).  
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The optimisation plots provided by the MS software (intensity versus 
optimised parameter value) were compared for different nebulisers and it was 
observed for all nebulisers and all analytes that only the optimal capillary 
voltage – the voltage applied between ESI nebuliser and MS entrance – changed 
significantly from nebuliser to nebuliser. Therefore all MS parameters exclud-
ing Capillary Voltage were individually optimised for analytes with the com-
mercial nebuliser and fixed for nebuliser parameters optimisation. The used MS 
ion optics and fragmentation parameters are presented in the Table A – 2. 
 
 
3.3.1. Testing different nebuliser parameters  
The primary optimisation of nebuliser parameters was carried out using a two-
level full factorial design model, where the parameter level values were chosen 
according to our previous experience (specified in chapter 1.10.3). The 
optimisation was performed using two types of samples: pesticides in solvent 
and pesticides in garlic extract. The results for pesticides (both solvent and 
garlic samples) and pharmaceuticals were analysed with ANOVA and a GLM 
model was used to estimate dependence of each analyte’s signal on nebuliser 
parameters. From ANOVA results (data not shown) it was observed that for the 
majority of analytes most of the parameters and two-parameter combinations 
influenced statistically significantly the peak areas of the analytes. Therefore, all 
parameters and two parameter interactions were chosen for all analytes into the 
GLM model. Even though the actual relation between the analyte signal and 
parameter values may not be linear the GLM model is a good approximation 
(data shown in section 1.14.2) for describing the effects of different nebuliser 
parameters on the analyte signal.  
The GLM coefficients for each analyte are given in Table A – 8. In Figure 
12 the coefficients were averaged over all analytes and samples, because we 
aim to find nebuliser parameters that are suitable for a wide range of analytes in 
both simple and complex matrices. The error bars indicate the standard 
deviations of the averages. As the parameter values were scaled and centred, 
before fitting the GLM model, comparison of the coefficients can be used for 
comparing the physical significance of the parameters and parameter combi-
nations. It can be seen from Figure 12 as well as from the non-averaged data in 
table A – 8, that for the analytes (both pesticides and pharmaceuticals) some of 
the nebuliser parameters tend to be significantly more important than others (in 
the parameter value ranges used in this study) and these effects are independent 
of the analyte and matrix. For example in our case the gas pressure in Capillary 
C tends to influence the MS response more significantly than the other studied 
parameters. Capillary B ID and Capillary C ID are somewhat less significant. 
All of these three parameter coefficients are also statistically significantly 
different from 0 according to the t-test, indicating their overall importance in 
nebulisation process for the variety of analytes and matrixes studied. The fact 
that optimisation results agree well for different analytes and different matrixes 
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(as indicated by the t-test) confirms that the 3R nebuliser with optimal parameters 
can be universally used for analytes of wide polarity range and matrixes of 
different complexity.  
 
 
Figure 12. GLM coefficient values for different parameters and parameter combinations 
(abbreviations described in section 1.10.3). The values are given as averages over all 
pesticides and error bars represent standard deviations of the average coefficients. Similar 
results were also observed for pharmaceuticals (see Appendices Table A – 8). 
 
 
3.3.2. Finding optimal nebuliser parameters and creating  
a model describing effects of different parameters 
The coefficients averaged over all analytes and matrices for the 3 most signi-
ficant parameters were used to predict the analytes signals:  
 
Sୟ୬ୟ୪୷୲ୣ = (0.37 ± 0.04) × B୍ୈୱ − (0.22 ± 0.05) × C୍ୈୱ + (0.95 ± 0.06) × Cpୱ (9) 
 
where Sanalyte is the scaled predicted analyte signal, B_IDs, C_IDs and Cps are the 
scaled values of Capillary B ID, Capillary C ID and gas pressure in Capillary C. 
Standard deviation of the obtained coefficients is presented as ±. Correlations 
between the predicted signals and measured signals (scaled within one analyte 
and sample type e.g. solvent or garlic extract) was studied for all analytes. For the 
majority of the compounds 60 to 80% of the signal variation (i.e. R2 between 0.6 
and 0.8) can be explained by the variation of only these three nebuliser 
parameters (Capillary B ID, Capillary C ID and gas pressure in Capillary C). 
The GLM model in our approximation is used as an indicative tool, therefore 
the descriptive properties of this model are sufficient according to the observed 
R2 values. Importantly, the correlation analysis for standard solutions and 
samples was carried out separately as our model only aims to account for signal 
variation due to nebuliser and not for signal variation due to matrices.  
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It can be concluded from these data that the major changes in ESI/MS signal 
can be described by changes in capillary dimensions and nebuliser gas pressure 
(Capillary C). It is clear that in the dimension range that was used in this work a 
capillary B with a wider ID and capillary C with smaller ID should be preferred, 
but first of all, and independently of the capillary dimensions, the increase of 
gas pressure in Capillary C increases analyte signal. On the other hand, the 
“conventional” nebuliser gas pressure (CA in Figure 12) is significantly less 
influential. In this study we have used gas pressures to describe the gas flow 
rates in the capillaries, because pressures are better accessible experimentally. It 
is of interest if the actual effect arises from gas pressure or flow rate (either 
volumetric ml/min or linear velocity mm/s). In order to answer this question we 
used two different capillary C-s (different ID – 90 and 175 um) at 5 different 
pressures (6 to 14 bar) resulting in 5 different gas flow rates for each 
Capillary C. Also 8 different eluent flow rates were used for each capillary C gas 
pressure. Thereafter we correlated the results for both Capillary C-s. The 
correlation between the results obtained with both capillary C-s was carried out 
and it was observed that the best correlation was observed if gas pressures (not 
flow rates) were used (R2 0.880 with gas pressure compared to R2 of 0.022 with 
gas flow rate). The slope of the correlation line was 0.959. Therefore we 
conclude that using the gas pressures in the GLM is justified.  
 
 
3.3.3. Influence of eluent flow rate on the ionisation  
In order to study the effect of eluent flow rate on the ionisation efficiency a 
model compound imazalil was chosen and the peak areas of imazalil were 
studied at different eluent flow rates (0.05 to 0.4 ml/min) and different Capillary 
C gas pressures (Figure 13A). It was observed that independently of the Capillary 
C gas pressure imazalil signals decreased with increasing eluent flow rate 
(maximum decrease observed was 2 times, eluent flow rate changed from 0.05 
to 0.4 ml/min, at Capillary C pressure 14 bar). This finding is very similar  
to that of Page et al.90, who observed that the ion transportation efficiency 
decreases with increasing mobile phase flow rate. The decrease of ion transport 
efficiency may be the major cause of this effect also in our instrument. On the 
other hand, independently of the eluent flow rate higher Capillary C gas pres-
sures yielded higher signal intensities, thereby indicating that higher capillary C 
gas pressure increases the number of desolvated ions reaching the mass ana-
lyser. The highest signal increase while using Capillary C pressure 14 bar 
instead of 6 bar was more than 4 times, occurring at flow rate 0.05 ml/min.  
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Additionally, the endplate current and capillary current – measuring the number 
of ions (including solvated ions) neutralised at the MS entrance and ion 
transportation capillary, respectively – were studied (Figure 13 B and C). It was 
observed that both higher eluent flow rates and higher gas pressures lead to the 
increase of the end plate and capillary current. The increase of endplate and 
capillary current with increasing gas pressure is most probably due to the fact 
that the spray plume widens if the inner nebuliser gas pressure increases. 
Therefore besides more ion entering the capillary, more ions also collide with 
the MS entrance. On the other hand increasing gas pressure increases MS 
signal. This means that even though more ions are lost in the MS ion optics, 
more ions also reach the ion trap. Therefore it can be concluded that increasing 
the inner capillary gas pressure increases the ionisation efficiency. It has been 
previously described by Page et al.90, that the net ion current entering the mass 
analyser is not the most important parameter affecting sensitivity. Even more 
important is the number of desolvated ions reaching mass analyser, as only 
these ions actually contribute to the useful signal. 
 
 
3.3.4. Universality of 3R nebuliser 
The 3R nebuliser with optimised parameters (capillary B ID 0.5 mm, C ID 
90 μm and capillary C pressure 14 bar) was compared with the commercial 
Agilent nebuliser originally implemented in the used MS system in order to 
evaluate the universality of the novel 3R ESI nebuliser. Comparison of sensitivity 
and LoD for 20 different analytes (Table 4) was done with both nebulisers. The 
analytes ranged from polar (oxamyl with logP= –0.5) to highly non-polar 
(etofenprox with logP=6.7). Four different sample matrices with varying comp-
lexity –ranging from solvent to the very complex garlic matrix – were used for 
pesticides (for 4 pharmaceuticals only solvent was used), resulting in 68 
analytematrix combinations. Within the same matrix the comparison of 
nebulisers was done on the same day in order to minimise variations due to 
other factors.  
Initial results72 indicated that 3R nebuliser might be more sensitive than 
commercial ESI nebuliser (when comparing the results of the 3R nebuliser with 
and without the inner gas capillary). Subsequent experiments during optimi-
sation showed the calibration graph slopes to be statistically insignificantly 
different for 3R nebuliser in comparison with commercial nebuliser.  
On the other hand, the achievable LoD values were found to be different for 
two nebulisers (LoD values are presented in Table 4). In the case of two 
pesticides – imazalil and spiroxamine – the sensitivity was very high with both 
nebulisers. Therefore the LoD in solvent was indicated to be below 
<0.0001 mg/kg, which is significantly below the required working range for 
pesticide analyses. The data obtained are interpreted in the context of significant  
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improvement for the ESI/MS users. We consider that the lowering of LoD by 
more than 2 times might be important for practical users (although even smaller 
changes can be statistically important). Altogether approximately 30% of the 
analytes showed significantly lower LoDs (improvement more than 2 times) 
with 3R nebuliser (24 out of 68 analyte-matrix combinations). It is worth 
mentioning that improvement was achieved not only for an easy matrix – 
solvent – but also for very troublesome matrices such as garlic and onion. Only 
3 samples out of 68 (4%) showed significantly higher (more than 2 times) LoD 
values with the new 3R nebuliser. The remaining analyte-matrix combinations 
did not show significant change of LoD. On the average (across all analytes and 
matrices) the 3R nebuliser gave LoD improvement of 2.5 times. That is higher 
than the average results reported in72 in initial results, where the average was 1.7 
times better for the 3R nebuliser in comparison with commercial nebuliser 
(according to the geometric mean). 
The reason for the lower LoDs of 3R nebuliser compared to the commercial 
nebuliser, while sensitivity was not affected, is revealed by looking at the chro-
matograms. Figure 14 displays the chromatograms of carbendazim with the 
native commercial nebuliser and 3R nebuliser. It is observed that in the case of 
the native nebuliser the background noise is around 50 times higher than with 
the 3R nebuliser. Even though these data are recorded in MS/MS mode this 
shows that on the average the 3R nebuliser has clear advantages over the native 
commercial nebuliser.  
 
 
Figure 14. Comparison of carbendazim chromatograms at 0.01 mg/kg in solvent with 
commercial (above) and 3R nebuliser (below). 
 
In addition to the universal applicability the 3R nebuliser also shows better 
robustness. The robustness of 3R nebuliser was compared with commercial 
nebuliser with 20 consecutive injections of garlic extract spiked with imazalil, 
carbendazim and thiabendazole (Figure 15).72 Garlic was chosen because it is a 
complex matrix giving more matrix effects than many others.89 For commercial 
nebuliser the signal decreased by 57% for imazalil with sudden decrease 
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starting from the 6th injection, while maximum decrease of 34% was observed 
for 3R nebuliser over a much smoother decline. 45% and 16% increase in signal 
was observed in case of carbendazim and thiabendazole, while for 3R nebuliser 
the corresponding numbers were 15% and 29%. While the results are worse for 
thiabendazole in case of 3R nebuliser, the sudden decline and the amplitude of 
the decline for the two other compounds are drastic for the commercial nebu-
liser. Also, during this work novel 3R nebuliser has been used for over four 
years without any need for replacement of details. On the other hand com-
mercial nebuliser needs maintenance (capillary replacement more than once a 
year) and it is prone to clogging as well as nebuliser capillary tip contamination. 
Thus it can be concluded that 3R nebuliser is more robust compared to 
commercial nebuliser. 
 
 
Figure 15. Comparison of robustness of the native commercial nebuliser (A) with the 
novel 3R nebuliser (B). Robustness was measured by change of the MS signal for either 
nebuliser during repetitive injections of garlic extract spiked with carbendazim, thia-
bendazole and imazalil. 
 
 
3.4. Practical applications of the novel 3R ESI source: 
neonicotinoids in honey 
The optimised nebuliser was compared with commercial nebuliser on a practical 
analysis example in order to determine how it performs under “field condi-
tions”. One important application is residue analysis, such as determination of 
neonicotinoids in honey samples. 
Neonicotinoids, e.g. imidacloprid and acetamiprid, are a relatively new class 
of insecticides. Neonicotinoids affect the nervous system of the insects through 
nicotinic acetyl choline receptors. These pesticides are widely used because 
they act as strong agonists, activating the nicotinic acetyl choline receptors of 
insects. However, the effect is not as significant for vertebrates. They are 
therefore highly toxic for insects, but are generally considered only moderately 
harmful to vertebrates.91–93 
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Besides determination of the exposure of bees to neonicotinoids, it is 
increasingly important to determine neonicotinoids in products consumed by 
humans. This is illustrated by a study published in 2014 on the analysis of 573 
fruit and 850 vegetable samples collected randomly from a market in the 
Aegean region in Turkey between 2010 and 2012. From 186 pesticide residues 
determined in the study, one of the three most frequently detected pesticides 
was acetamiprid (in over 20 fruit and over 120 vegetable samples). In addition, 
imidacloprid was frequently detected (in over 20 fruit and over 40 vegetable 
samples). Thiamethoxam was observed less frequently.2  
 
 
3.4.1. Results of nebulisers comparison 
For the analysis of honey samples the 3R nebuliser and the native ESI nebuliser 
were compared in terms of fitness for purpose. The MRLs of neonicotinoid 
pesticides are low. Thus, the analysis of neonicotinoids is a trace analysis and it 
is important to choose the nebuliser that gives the lowest LoDs and has linear 
ranges extending to low concentrations. Thus the two nebulisers were compared 
by LoD, linear range, process efficiency and repeatability (as RSD). 
The LoD results for commercial nebuliser were 0.088 mg/kg, 0.030 mg/kg, 
0.020 mg/kg and 0.0031 mg/kg for thiamethoxam, imidacloprid, acetamiprid 
and thiacloprid, respectively. For 3R the LoD values were 0.10 mg/kg, 
0.018 mg/kg, 0.0056 mg/kg and 0.0014 mg/kg for thiamethoxam, imidacloprid, 
acetamiprid and thiacloprid, respectively. In the case of LoD values 3R presents 
advantages compared to the commercial nebuliser. Ratios of LoD values of 3R 
nebuliser to commercial nebuliser give 0.9 for thiamethoxam, 1.7 for imidacloprid, 
3.7 for acetamiprid and 2.2 for thiacloprid with average of 2.1 times improved 
LoD in case of 3R nebuliser. Literature overview shows that the LoD for 
neonicotinoids in honey were in the range of 0.15–160 μg/kg for thiamethoxam, 
0.03–33 μg/kg for imidacloprid, 0.04–0.5 μg/kg for acetamiprid and 0.02–
0.5 μg/kg for thiacloprid77,94–98. While the values for thiamethoxam and 
imidacloprid obtained in this work are within the range found in literature, for 
acetamiprid and thiacloprid they are 3–11 times higher for 3R nebuliser and 6–40 
times higher with the commercial nebuliser. However, LoD values are strongly 
dependent on the approach used for their determination.80 Our previous 
knowledge shows that the approach used in this work gives very conservative 
values and thus results in significantly higher values than LoD estimates based 
on signal-noise ratio. Because the difference between LoQ and LoD is usually 
only multiplication of the latter with 3.3 or 3, the obtained LoQ values are also 
more conservative due to the method used for LoD determination.  
In Table 5 and Figure 16 the linear ranges and LoQ values for both nebulisers 
and MRL values are shown. Comparing LoQ values with the MRL values shows 
that with the commercial nebuliser only LoQ for thiacloprid is below the MRL 
value, but with the 3R nebuliser both acetamiprid and thiacloprid LoQ values 
were below MRL and LoQ for imidacloprid is at MRL. 
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As can be seen in Table 5 the linear range is better or comparable for the 3R 
nebuliser (as compared to the commercial nebuliser). The linear range extends 
to lower concentrations for all neonicotinoids except thiamethoxam. For 
thiacloprid the linear range of the 3R nebuliser is stretching to both larger and 
smaller concentrations compared to commercial nebuliser, while for the latter 
linear range barely reaches the LoQ value. It can be assumed that concentrations 
of the 4 neonicotinoids in real honey samples are more likely at smaller 
concentrations below MRL values, thus it is preferred to use the 3R nebuliser 
for determination of neonicotinoids in honey samples.  
 
 
Figure 16. Comparison of linear ranges and LoQs. 
Table 5. Comparison of novel 3 nebuliser with commercial nebuliser. 
m/z transitions LoQ (mg/kg) MRL 
(mg/kg)
Linear range (mg/kg) 
Precur-
sor ion 
Product  
ions 
Com-
mercial 3R 
Com-
mercial 3R 
thiamethoxam 314 210b, 180 0.27 0.31 NAa 0.27–2.0 0.31–2.0 
imidacloprid 256 175b, 209 0.092 0.055 0.05 0.092–0.62 0.055–0.31 
acetamiprid 223 126b, 187 0.062 0.017 0.05 0.062–0.624 0.017–0.16 
thiacloprid 253 126b, 186, 226 0.0095 0.0043 0.2 0.012–0.078 0.0047–0.16 
a MRL for thiamethoxam (0.01 mg/kg) is given as sum of thiamethoxam and clothianidin,  
b quantitation ion. 
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According to SANCO/12571/2013 suggestions, repeatability values should be 
below 20%. As can be seen in Figure 17 the pooled RSD values of the 3R nebuliser 
were below the suggested 20%, with only upper confidence limit for thiacloprid 
at low end of linear range slightly over 20%. For commercial nebuliser, pooled 
RSD values were also below the limit, but upper confidence intervals for 
acetamiprid and thiamethoxam stretched significantly above the limit. 
According to SANCO, the recovery values should be between 70–120%. In 
the context of LC/ESI/MS it is appropriate to compare these limits to process 
efficiency (PE) not to recovery, because PE also takes into account possible 
ionisation suppression. In Figure 18 the PE values with the SANCO limits and 
confidence intervals are shown. For 3 of the neonicotinoids – thiamethoxam, 
imidacloprid, thiacloprid – the PE values with confidence intervals were within 
recommended limits. For acetamiprid the averages were outside the limits at 
high end of the linear range and lower confidence intervals stretch outside of 
limits in case of low end of linear range. This however was not a problem in the 
current analysis since acetamiprid was expected at low concentrations (if at all) 
and PE values at low end of linear range were acceptable. 
Considering the results from validation the 3R nebuliser is superior to com-
mercial nebuliser for the residue analysis of the 4 neonicotinoids in honey and 
can be recommended for analysis of neonicotinoids in honey samples. Although 
honey samples can vary a lot in composition and only 3 different honey sorts 
were used for validation, it is safe enough to assume that the 3R nebuliser 
would prove also more efficient than commercial nebuliser for other honey 
types based on validation results. 
 
 
Figure 17. Comparison of RSD values for all analytes with both ESI nebulisers used. 
Error bars denote confidence interval at 95%. Suggested RSD values by SANCO are 
shown as lines at 20%. 
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Figure 18. Comparison of process efficiency values for all analytes with both ESI 
nebulisers used. Error bars denote confidence interval at 95%. Suggested process effi-
ciency values by SANCO should be between lines at 70% and 120%. 
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SUMMARY 
There are numerous novel developments aiming to improve the interface 
between LC and MS. Novel commercial ion sources need to be compared with 
each other in order to evaluate their advantages. For some novel ion sources the 
comparison has been done in this study, occasionally with surprising results. 
Comparison of the conventional ESI source with some of the newer develop-
ments in commercial ionisation sources, such as HESI, MMI (ESI-APCI) and 
APPI sources demonstrated that the ESI source is on an average the most robust 
and sensitive method for generating ions in the interface of LC and MS. While 
HESI proved to be superior in sensitivity and LoD over most other sources used 
in comparison and DA-APPI was robust when considering matrix effects, only 
ESI was among the leaders in all comparison parameters. The LoD values of 
ESI were comparable to HESI and the best matrix effects were observed with 
ESI source. ESI source also proved to be comparable or better in repeatability, 
linear ranges and sensitivity with respect to other sources. 
The novel 3R nebuliser for ESI source recently developed in our group was 
compared to the conventional ESI source. Optimization of nebuliser parameters 
was successfully concluded during the study. Analysis of the main nebuliser 
parameters affecting the ionisation showed that the inner gas capillary pressure 
and internal diameter as well as the liquid capillary internal diameter had the 
strongest influence on the results. The importance of the outer gas capillary 
pressure, responsible of the nebulisation in the conventional ESI nebuliser, 
proved to be much less important than the gas pressure in the inner gas 
capillary, showing the advantage of the novel approach to ESI nebuliser.  
The 3R nebuliser was demonstrated to give on the average 2.5 times (up to 
200 times) lower limits of detection and less noise than the native commercial 
ESI source. After the optimisation of the novel nebuliser the advantage of lower 
LoDs became even more pronounced. It was also shown that the 3R nebuliser is 
more robust than the conventional one. The advantages of the 3R nebuliser were 
put to test with a practical analysis of neonicotinoids in honey. It is a trace 
analysis and thus is demanding of the ionisation source to give good results with 
as low LoD as possible. In the comparison with the native commercial nebuliser 
the 3R nebuliser proved to be comparable or better. 
The aims of the thesis were fulfilled successfully, but many more novel ion 
source developments need to be evaluated and the work on improving the 
LC/MS method as such is far from done. This study is expected to add valuable 
information for the improvement of the LC/MS method and proposes a new 
direction for the improvement of ESI source.  
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SUMMARY IN ESTONIAN 
“Uudsete massispektromeetria ionisatsiooniallikate  
võrdlemine ja optimeerimine” 
Vedelikkromatograafia-massispektromeetria (LC/MS) on laialt kasutatav meetod 
väga mitmekesiste analüüside teostamiseks nii rutiin- kui teaduslaborites. Ioni-
satsiooniallikas on kahe meetodi (vedelikkromatograafia ja massispektromeet-
ria) ühendamiseks oluline liides, mille abil tekitatakse kromatograafist tulevast 
vedelikust analüüdimolekulide ioonid, mida analüüsitakse massispektromeetriga. 
Erinevaid ionisatsiooniallikaid on mitmeid ning pidevalt täiendatakse olemas-
olevaid ja leiutatakse uusi. Seetõttu on vajalik võrrelda erinevaid uusi ionisat-
siooniallikaid, et leida millised on spetsiifilise töö jaoks parimad. 
Antud töö käigus võrreldi mitmeid uusi ionisatsiooniallikaid kommertsiaal-
selt levinud elektropihustus-ionisatsiooni allikaga (ESI). Võrdluses kasutati 
atmosfäärirõhulist fotoionisatsiooni allikat (APPI), kuumutatud elektropihustus-
ionisatsiooni (HESI) ja mitmikmeetoditega (MMI) allikat. Võrdluseks kasu-
tatavad parameetrid olid avastamispiir (LoD), tundlikkus, maatriksefektid (ME), 
lineaarne ala ja korduvus. Parimaid tulemusi saadi kommertsiaalse ESI allikaga. 
Samuti häid tulemusi näitas HESI allikas tundlikkuse osas, kuid jäi märkimis-
väärselt alla ME tulemuste poolest ESI ja dopandiga abistatud APPI allikatele. 
Kehvimad tulemused olid MMI allikatega. 
Samuti oli töö eesmärgiks meie töögrupis eelnevalt väljatöötatud uudse ESI 
allika pihusti (3R) optimeerimine, mis viidi edukalt lõpule. Optimeerimise tule-
mused näitavad, et ionisatsiooni mõjutab oluliselt enam vedelikukapillaari sees 
asuv pihustusgaasi kapillaar võrreldes kommertisaalsel allika välimise pihustus-
gaasi kapillaariga. Uudse 3R pihusti eelised seisnevad peamiselt madalamates 
avastamispiirides ja robustsuses võrreldes kommertsiaalse allikaga. 
Samuti täideti edukalt uudse pihustiga seotud teine eesmärk: võrreldi kom-
mertsiaalse pihustiga praktilise analüüsi näitel. Selleks oli jälgede määramine 
neonikotinoidide analüüsil meeproovidest. 3R pihustile leiti madalamale ula-
tuvad lineaarsed alad, madalamad või samaväärsed avastamispiirid ja parem 
korduvus võrreldes kommertsiaalse allikaga.  
Antud töös leitud erinevate ionisatsiooniallikate võrdlusandmed ning uudse 
ESI pihusti iseloomustamisel leitud eelised lisavad olulist informatsiooni väga 
mitmekesisele MS ionisatsiooniallikate temaatikale. Teadlased püüdlevad ühest 
küljest aina universaalsemate allikate poole, kuid samas otsitakse allikaid väga 
spetsiifiliste analüüside teostamiseks, mis annaksid parimaid tulemusi. Selleks 
on vajalik aina uuesti võrrelda praeguseid parimaid allikaid uudsete leiutistega, 
et leida effektiivseim liides LC/MS meetodile. 
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APPENDICES 
Table A – 1. Compound fragmentation data and acquisition time windows. For two 
compounds denoted with asterisk after the compound name (*) confirmatory fragment was 
not observed. Asterisk (*) at the product ion marks the quantitative ion. Retention time 
window was 0.6 min for all compounds. CE marks the collision energy of fragmentation. 
Name 
Pre-
cursor 
ion 
Pro-
duct 
ion 
CE 
(V) 
Ret. 
time 
(min) Name 
Pre- 
cursor 
ion 
Pro-
duct 
ion 
CE 
(V) 
Ret. 
time 
(min) 
acetamiprid 223 187 20 2.373 methiocarb-
sulfoxide 
242 185* 15 1.927 
  126* 20 2.373 168 15 1.927 
azoxystrobin 404 372 24 4.379 methoxychlor * 345 161* 30 4.786 
  344 24 4.379 metribuzin 215 187* 20 3.168 
  329* 36 4.379   145 20 3.168 
benalaxyl 326 208 20 5.057 myclobutanil 289 170 30 4.37 
  148* 20 5.057   125* 30 4.37 
bitertanol 338 269* 10 4.635 paclobutrazol 294 165 30 4.001 
  251 10 4.635   139 30 4.001 
bupirimate 317 166 30 4.004   125* 30 4.001 
  108* 30 4.004 
pirimiphos-ethyl 
334 198* 24 5.988 
buprofezin 306 201 20 5.27 182 20 5.988 
  116* 20 5.27 propiconazole 342 342 20 4.783 
chloridazon 222 193 24 2.165   159* 20 4.783 
  104* 24 2.165 propoxur 210 168* 10 3.258 
ditalimfos 300 244 10 4.834   111 10 3.258 
  148* 10 4.834 pymetrozine * 218 105* 20 0.507 
epoxiconazole 330 121* 20 4.389 pyrazophos 374 222 20 5.253 
  101 40 4.389   194* 36 5.253 
fenhexamid 302 178 35 4.463 pyrimethanil 200 183 20 3.201 
  143* 35 4.463   107* 20 3.201 
fenpropimorph 304 147* 36 3.235 quinoxyfen 308 272 28 5.629 
  130 24 3.235   197* 36 5.629 
  117 20 3.235 spiroxamine 298 144* 30 3.237 
fluquinconazole 376 349 20 4.503   100 30 3.237 
  307* 28 4.503 tebufenozide 353 297* 10 4.9 
flusilazole 316 247 20 4.516   133 10 4.9 
  165* 28 4.516 thiacloprid 253 186 20 2.707 
hexythiazox 353 228 20 6.102   126* 20 2.707 
  168* 20 6.102 thiamethoxam 292 211* 15 1.814 
imazalil 297 159* 30 2.818   181 15 1.814 
  109 30 2.818 thiophanate-
methyl 
343 192 20 3.2 
imidacloprid 256 209 20 2.218 151* 20 3.2 
  175* 20 2.218 triasulfuron 402 167* 20 3.383 
indoxacarb 528 203* 35 5.502   141 20 3.383 
  150 35 5.502 triazophos 314 162* 20 4.761 
mepanipyrim 224 209 20 4.587   119 40 4.761 
  183 20 4.587 trifloxystrobin 409 206 15 5.538 
methiocarb 226 169 10 4.16   186* 15 5.538 
  122 30 4.16 vamidothion 289 146* 20 1.913 
  121* 10 4.16   118 20 1.913 
methiocarb-
sulfone 
258 201 10 2.578 mepanipyrim   106* 20 4.587 
122* 10 2.578         
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Table A – 2. MS ion optics and fragmentation parameters for analytes used in the optimisa-
tion study of 3R nebulizer. 
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oxamyl 7.8 55 99 13 1.9 44 112 –4.7 –60 0.66 90 242 185 
thiamethoxam 9.1 
47 50 11 2.2 44 95 –4.2 –56
3.00 113 292 211 
carbendazim 8.5 0.65 84 192 160 
imidacloprid 10.3 
54 95 11 2.1 44 116 –4.4 –63
2 92 256 209 
thiabendazole 9.6 1 105 202 175 
acetamiprid 11.2 
65 120 12 2.0 53 125 –3.5 –65
0.54 76 223 126 
vamidothion 10.9 0.62 103 310 146 
thiacloprid 12.0 44 112 13 1.7 50 120 –4.2 –66 2 92 253 126 
spiroxamine 15.2 
61 124 15 2.4 53 107 –4.2 –66
0.71 95 298 144 
imazalil 13.9 2 125 297 201 
mepanipyrim 17.3 
60 125 12 2.0 53 125 –4.0 –70
0.57 110 224 183 
fluquinconazole 17.1 0.84 182 376 349 
methiocarb 16.5 0.42 99 226 169 
buprofezin 18.8 
45 100 12 2.5 44 125 –4.2 –65
0.57 61 306 201 
hexythiazox 19.3 0.54 74 353 228 
etofenprox 20.9 47 124 18 2.4 44 173 –4.4 –78 0.50 86 359 189 
M
et
ho
d 
2 
fo
r 
ph
ar
m
ac
eu
tic
al
s 
norfloxacin  
40 128 12 1.7 40 187 –5.0 –60
0.79 129 320 276 
ciprofloxacin  0.75 166 332 288 
ofloxacin  0.50 99 362 261 
sulfadimethoxine  0.50 110 311 245 
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Table A – 3. Default parameters of different ionisation modes used in Paper III. 
Ioni-
sation 
mode 
Gas 
temp. 
(⁰C) 
Gas  
flow  
(14 l/min) 
Nebu-
liser 
pressure 
(psi) 
Capil-
lary 
voltage 
(V) 
Vapo-
riser 
temp. 
(⁰C) 
Corona 
current 
(μA) 
Char-
ging 
voltage 
(V) 
Sheath 
gas 
temp. 
(⁰C) 
Sheath 
gas 
flow 
(l/min) 
Nozzle 
Vol-
tage 
(V) 
HESI 200 14 20 3000       400 11 1500 
ESI 200 14 15 4000       
MMI  200 14 60 2500 200 4 2000     
MMI-
ESI 200 14 60 2500 200   2000     
MMI-
APCI 200 14 60 2500 200 4      
APPI 200 14 40 2000 350           
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Table A – 4. The molecular parameters values used in PCA of LoD and ME. The logP 
values were calculated as averages over several data sources, because there was no way 
to discriminate between different sources. 
Compound logPa MW pKa tR (min) 
pymetrozine  –0.0299,100,101 217 4.1102 0.58 
thiamethoxam 0.5799,100,103 292 1104 1.83 
vamidothion  –2.0299,105 287  –0.8104 1.93 
methiocarb sulfoxide 1.07100 241  –1.6104 1.96 
chloridazon 1.1799,106 222 0.7104 2.18 
imidacloprid 0.7699,100,107 256 2.3104,108 2.21 
acetamiprid 1.3699,100,101 223 0.7109 2.39 
methiocarb sulfone 1.04100 257  –1.6104 2.60 
thiacloprid 1.7499,100,110 253 0.8104,108 2.77 
imazalil 3.4499,107 297 6.5111 2.84 
thiophanate-methyl 1.9299,112 342  –0.5104 3.19 
metribuzin 1.7399,100,107 214 7.1113 3.13 
pyrimethanil 2.7699,101 199 3.5101 3.23 
fenpropimorph 4.6999,100,114 303 7115 3.34 
spiroxamine 3.8699,100,116 297 8.8117 3.34 
propoxur 1.4399,100,107 209  –1.5104 3.26 
triasulfuron  1.2299,100 402 2.6104 3.38 
bupirimate 3.47107 316 4.4118 3.99 
paclobutrazol 3.1699,100,119 294 2.4104,108 4.03 
methiocarb 2.9599,100,107 225  –1.5104 4.16 
azoxystrobin 3.4699,100,120 403  –0.2104,108 4.40 
epoxiconazole 3.3799,107 330 2.5104,108 4.42 
myclobutanil 3.0799,100,107 289 2.3104 4.36 
fenhexamid 4.5699,100,101 302  –2.7108 4.42 
fluquinconazole 3.4499,121 376 0.9104 4.53 
flusilazole 3.6199,100,122 315 2.5123 4.60 
mepanipyrim 5.1999,121 223 2.9124 4.59 
bitertanol 4.0999,125 337 2.3104 4.64 
propiconazole 3.8499,101 342 2.6104,108 4.87 
triazophos 3.4799, 107 313  –0.2104 4.74 
methoxychlor 5.2499, 100,112 346  –4.8108 4.87 
ditalimfos 3.299 299  –7.5104,108 4.78 
tebufenozide 4.5399,100,107 352  –2.2104 4.89 
benalaxyl 3.4999,107 325  –1.1104,108 5.04 
pyrazophos 3.899,107 373  –1.4104 5.23 
buprofezin 4.299,100,101 305 4.9104,126 5.13 
indoxacarb 4.5699,100,101 528  –1.6104,108 5.44 
trifloxystrobin 4.5499,100,101 408 2.4108 5.49 
quinoxyfen 4.999,120 308 3.6120 5.69 
pirimiphos-ethyl 4.999,107 333 5104,108 5.91 
hexythiazox  4.0699,100 353 –7108 6.01 
a calculated as averages over several sources 
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Table A – 6. LoD values for 41 pesticides using 7 different ionisation modes, together 
with retention times. Grey background means that qualitative ion was absent. Orange 
background means that either qualitative or both ions were not detected. Yellow back-
ground means that qualitative ion was not detected at calculated LoD value and the 
lowest concentration where qualitative ion was observed was used as the LoD value. 
LoD (μg/kg) 
compound tR MMI MMI-APCI MMI-ESI ESI HESI APPI DA-APPI 
pymetrozine 0.58 1.0 1.2 0.45 0.87 1.4 2.1 2.0 
thiamethoxam 1.83 0.24 0.93 0.27 0.20 1.7 2.5 3.2 
vamidothion 1.93 1.2 5.9 0.74 0.80 1.0 35 9.6 
methiocarb sulfoxide 1.96 0.25 2.5 0.18 0.27 0.61 1.7 0.75 
chloridazon 2.18 0.34 1.4 0.26 0.12 0.42 25 2.5 
imidacloprid 2.21 0.53 3.2 0.63 0.30 1.1 2.0 0.95 
acetamiprid 2.39 7.5 50 7.5 2.5 2.5 25 5.0 
methiocarb sulfone 2.60 5.0 53 4.8 0.29 0.71   75 
thiacloprid 2.77 0.26 10 2.5 0.13 0.73 1.4 0.75 
imazalil 2.84 0.47 1.5 0.92 0.33 0.26 10 10 
thiophanate-methyl 3.19 50     75 46     
metribuzin 3.13 2.5 25 2.5 0.75 0.36 2.4 10 
pyrimethanil 3.23 1.4 29 1.0 0.15 0.13 2.7 6.6 
fenpropimorph 3.34 0.18 1.3 0.59 0.091 0.089 2.1 1.8 
spiroxamine 3.34 0.13 1.5 0.19 0.063 0.086 2.6 1.1 
propoxur 3.26 1.0 4.0 0.43 0.29 0.71 25 7.5 
triasulfuron  3.38 1.4 16 0.45 0.21 0.28     
bupirimate 4.00 0.12 1.4 0.48 0.060 0.075 2.2 0.64 
paclobutrazol 4.03 3.7 90 1.5 0.50 0.44 5.7 13 
methiocarb 4.16 2.4 58 1.9 0.15 0.17 55 21 
azoxystrobin 4.40 0.61 7.7 2.2 0.11 0.18 34 3.8 
epoxiconazole 4.42 0.75 12 0.92 0.090 0.14 2.2 2.1 
myclobutanil 4.36 100 49 1.6 10 25 3.6 3.0 
fenhexamid 4.42 25   39 5.0 1.2 72 13 
fluquinconazole 4.53 6.5 71 10 0.21 0.11 6.3 6.1 
flusilazole 4.60 0.43 4.3 0.94 0.044 0.028 2.2 0.71 
mepanipyrim 4.59 2.9 163 9.0 0.21 0.14 5.0 2.2 
bitertanol 4.64 6.2 46 20 1.1 1.6 16 23 
propiconazole 4.87 2.0 10 2.0 0.25 0.040 1.9 0.67 
triazophos 4.74 0.38 3.4 0.48 0.047 0.11 1.6 0.73 
methoxychlor 4.87 7.9 90 30.8 0.34 0.43 7.9 10 
ditalimfos 4.78 3.3 43 12 0.13 0.14 217 39 
tebufenozide 4.89 3.7 57 5.5 0.11 0.21 25 27 
benalaxyl 5.04 0.55 5.9 0.45 0.057 0.15 2.2 0.39 
pyrazophos 5.23 0.37 4.7 0.52 0.12 0.17 1.7 0.34 
buprofezin 5.13 0.34 4.1 0.67 0.14 0.19 2.1 2.7 
indoxacarb 5.44 7.3 26 9.8 0.39 0.21 9.2 14 
trifloxystrobin 5.50 1.5 5.8 0.69 0.028 0.017 1.4 0.35 
quinoxyfen 5.69 2.7 8.7 2.0 0.049 0.034 2.1 0.36 
pirimiphos-ethyl 5.91 0.31 6.0 0.30 0.031 0.062 1.5 0.29 
hexythiazox  6.01 18 33 30 0.090 0.021 45 8.3 
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Table A – 7. Sensitivity (slopes) values for 7 different ionisation modes for 41 pesticides. 
Slopes of calibration graphs 
compound MMI MMI-APCI MMI-ESI ESI HESI APPI DA-APPI 
pymetrozine 2.5•105 1.9•104 2.5•105 4.1•105 4.1•106 4.7•104 2.2•105 
thiamethoxam 1.3•105 1.2•104 1.2•105 2.3•105 2.5•106 1.3•104 4.0•104 
vamidothion 1.6•104 1.5•103 1.8•104 1.9•104 2.4•105 9.6•102 3.2•103 
methiocarb 
sulfoxide 6.1•105 6.1•104 6.5•105 9.5•105 7.5•106 8.4•104 2.8•105 
chloridazon 2.6•105 2.0•104 2.5•105 4.9•105 6.1•106 3.4•104 9.2•104 
imidacloprid 6.9•104 7.8•103 6.1•104 1.1•105 1.1•106 2.8•104 7.9•104 
acetamiprid 2.9•105 2.5•104 2.5•105 6.0•105 5.6•106 7.8•104 2.4•105 
methiocarb sulfone 5.6•103 1.8•103 4.8•103 1.8•105 5.0•105 * * 
thiacloprid 2.6•105 2.7•104 2.4•105 8.4•105 8.7•106 7.7•104 2.5•105 
imazalil 2.1•105 1.7•104 1.9•105 1.6•105 1.8•106 4.6•103 1.6•104 
thiophanate-methyl * * * * * * * 
metribuzin 5.9•104 3.8•103 7.1•104 6.8•105 4.2•106 4.2•104 1.4•105 
pyrimethanil 3.1•104 2.1•103 3.4•104 3.9•105 4.5•106 2.8•104 1.3•105 
fenpropimorph 7.2•105 * 7.0•105 8.0•105 7.8•106 1.1•104 3.8•104 
spiroxamine 2.1•106 8.7•104 1.7•106 2.0•106 2.1•107 2.4•104 9.2•104 
propoxur 9.7•104 8.1•103 9.3•104 5.6•105 5.5•106 7.3•103 3.9•104 
triasulfuron 4.5•104 6.5•102 2.9•104 1.7•105 2.3•106 * * 
bupirimate 2.0•105 1.9•104 1.7•105 5.9•105 6.4•106 2.3•104 8.5•104 
paclobutrazol 7.8•103 * 7.5•103 1.2•105 1.0•106 3.2•103 9.0•103 
methiocarb 1.7•104 * 1.3•104 6.9•105 3.2•106 6.6•102 1.3•104 
azoxystrobin 1.1•105 * 1.0•105 6.4•105 1.2•107 2.3•104 4.6•104 
epoxiconazole 6.2•104 * 6.7•104 9.6•105 7.6•106 3.2•104 7.4•104 
myclobutanil 1.5•104 * 1.7•104 2.0•105 1.2•106 1.2•104 2.9•104 
fenhexamid 1.4•103 * * 1.8•104 2.1•105 * * 
fluquinconazole 8.2•103 * 8.4•104 2.2•105 1.5•106 4.0•103 1.4•104 
flusilazole 1.0•105 * 8.4•104 1.6•106 1.6•107 5.9•104 1.2•105 
mepanipyrim 1.7•104 * * 3.6•105 3.5•106 1.0•104 5.1•104 
bitertanol 4.4•103 * * 9.1•104 5.0•105 * * 
propiconazole 3.7•104 * 4.7•104 8.0•105 7.5•106 2.9•104 7.2•104 
triazophos 2.8•105 1.7•104 2.3•105 2.0•106 2.8•107 6.7•104 2.3•105 
methoxychlor 3.0•103 * * 6.8•104 6.4•105 2.4•103 6.5•103 
ditalimfos 1.0•104 * * 5.6•105 1.0•107 * * 
tebufenozide 8.5•103 * * 2.9•105 1.5•106 1.2•103 4.8•103 
benalaxyl 7.9•104 * * 1.3•106 2.4•107 3.4•104 1.4•105 
pyrazophos 5.3•104 * 7.1•104 5.8•105 * 3.3•104 8.9•104 
buprofezin 6.1•104 * 5.1•104 8.2•105 9.0•106 8.5•103 2.5•104 
indoxacarb 4.5•103 * 6.5•103 4.8•104 * * 6.8•103 
trifloxystrobin * * * 1.0•106 3.2•107 2.9•104 8.1•104 
quinoxyfen 1.9•104 * * 1.3•106 1.9•107 2.9•104 9.3•104 
pirimiphos-ethyl 2.6•105 * 4.6•105 7.5•106 1.4•108 5.1•104 1.8•105 
hexythiazox 3.5•103 * 3.1•103 8.7•104 5.2•106 1.3•103 6.8•103 
* Not enough points on the calibration graph 
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Curriculum Vitae in English 
I Personal information 
1.  Name: Asko Laaniste 
2.  Date of birth: 21st of September, 1987 
3.  Citizenship: estonian 
4.  Address: Tiigi 57–10, Tartu 
 Phone, e-mail:  58313727 asko.laaniste@gmail.com 
5.  Current position: University of Tartu, chemist 
6.  Education:  2012–…, University of Tartu, doctoral studies  
  2010–2012, University of Tartu, master’s studies, MSc  
  2007–2010, University of Tartu, bachelor’s studies, BSc  
7.  Language skills:  estonian mother tongue  
  english fluent in speech and writing  
  japanese basic understanding of speech  
8.  Professional career: 01.2014 – … University of Tartu, chemist 
 
 
II Research and development work 
1. Main fields of research: 
LC/MS, method validation, sample pretreatment, pesticides, HPLC, mono-
lithic columns 
 
2. Publications: 
Anneli Kruve, Ivo Leito, Koit Herodes, Asko Laaniste, Rünno Lõhmus, 
Enhanced Nebulization Efficiency of Electrospray Mass Spectrometry: 
Improved Sensitivity and Detection Limit, J. Am. Soc. Mass Spectrom. 2012, 
23, 2051–2054 
Asko Laaniste, Anneli Kruve, Ivo Leito, Ensuring repeatability and robustness 
of poly(glycidyl methacrylate-co-ethylene dimethacrylate) HPLC monolithic 
columns of 3 mm id through covalent bonding to the column wall, J. Sep. 
Sci., 2013, 36, 2458–2463 
Asko Laaniste, Audrey Marechal, Racha El-Debs, Jerome Randon, Vincent 
Dugas, Claire Demesmay, “Thiol-ene” photoclick chemistry as a rapid and 
localizable functionalization pathway for silica capillary monolithic columns, 
J. Chromatogr. A, 2014, 1355, 296–300 
Audrey Marechal, Asko Laaniste, Racha El-Debs, Vincent Dugas, Claire 
Demesmay Versatile ene-thiol photoclick reaction for preparation of multi-
modal monolithic silica capillary columns, J. Chromatogr. A. 2014, 1365, 
140–147 
Jaanus Liigand, Anneli Kruve, Piia Liigand, Asko Laaniste, Marion Girod, 
Rodolphe Antoine, Ivo Leito, Transferability of the electrospray ionization 
efficiency scale between different instruments, J. Am. Soc. Mass Spectrom., 
2015, 26, 1923–30. 
 144 
Asko Laaniste, Anneli Kruve, Ivo Leito, Riin Rebane, Rünno Lõhmus, Ants 
Lõhmus, Fredrik Punga, Determination of neonicotinoids in Estonian honey 
by LC/ESI/MS with novel nebulizer, Journal of Environmental Science and 
Health, Part B, accepted for publication. 
Asko Laaniste, Ivo Leito, Anneli Kruve, Comparison of different ionization 
sources for the LC/MS analysis of pesticides, submitted to Rapid Commu-
nications in Mass Spectrometry. 
 
3. Research grants and scholarships: 
2013 –  Kristjan Jaak Scholarships for part-time studies in Lyon, France. 
2014 –  Doctoral school scholarship for participation in 38th ISEAC. 
2015 –  Estonian Students Fund in USA for financial support to worthy Esto-
nian candidates, who demonstrate through academic excellence and 
community leadership their capacity for, and commitment to, making a 
contribution to Estonian society. 
2015 –  Kristjan Jaak Scholarships for participation in HPLC 2016 conference. 
 
4. Other administrative and professional activities: 
ValChrom project “Development of software for validation of chromatographic 
methods” (with registration number 3.2.1201.13-0020) under the sub-
measure “Supporting the development of R&D of info and communication 
technology” funded by the EU Regional Development Fund. 
Roles in the project (10.2015 – end of project in 08.2015): one of the software 
testers and developers for correspondence with validation guidelines (ICH, 
AOAC, EuraChem, IUPAC, EMA, FDA, NordVal); programming of the 
ValChrom software on QureDesign platform, overview of the progress of 
testing, promoting the program at HPLC 2015. 
 
III Teaching activities 
Analüütilise keemia praktikum I 
Since 2007 actively participated in popularization of science amongst elementary 
and high school students. Had a leading role in development and organization 
of chemistry workshop for “Teaduslaager” 2009–2014 (science camp for ele-
mentary school students on summers) and chemistry workshop for “Õpikojad” 
since 2010 (year-long practical workshops for elementary and high school 
students). 
Also part of Estonian Olympiad committee since 2012, responsible for 
organization of the olympiad, generation of the exercises for the participants 
and training of Estonian students for International Chemistry Olympiad. Also 
a volunteer for European Science Olympiad in 2016. 
 
IV Professional self-improvement and conferences 
30.11.2013 – Training for teaching assistants, Tartu, Eesti. 
02.–07.2013 – Visited the 1st University in Lyon for 5 months, studying 
functionalization of monolithic silica columns in prof. J. Randon’s group. 
 145 
11. October 2013 – Eesti XXXIII Keemiapäevad (Estonian XXXIII Chemistry 
Days). 
04.–05. March 2014 – TÜ and TTÜ collaborative doctoral school’s conference 
“FMTDK Teaduskonverents 2014”. 
16.–20. June 2014 – The 38th International Symposium on Environmental Ana-
lytical Chemistry. 
Spring 2015. – Estimation of measurement uncertainty in chemical analysis, 
MOOC, Tartu, Eesti. 
21.06.2015. – SFC – Principles, Instrumentation, Method Development, and Appli-
cations, Geneva, Switzerland. 
21.–25. June 2015 – 42nd Symposium on high performance liquid phase separations 
and related techniques (HPLC 2015). 
09.–10.06.2016. – 16th International Chromatography School, Zagreb. 
19.–24.06.2016. – 44th International Symposium on high performance liquid phase 
separations and related techniques (HPLC 2016), San Francisco, USA. 
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Curriculum Vitae in Estonian 
I Üldandmed 
1. Nimi: Asko Laaniste 
2. Sünniaeg: 21.09.1987 
3. Kodakondsus: eestlane 
4. Aadress Tiigi 57–10, Tartu 
Telefon, E-mail: 58313727 asko.laaniste@gmail.com 
5. Praegune töökoht: Tartu Ülikool, keemik 
6. Haridus: 2012 …, Tartu Ülikool, doktoriõpe 
 2010 2012, Tartu Ülikool, magistriõpe, MSc 
 2007 2010, Tartu Ülikool, bakalaureuseõpe, BSc 
7. Keelteoskus: eesti keel emakeel 
 inglise keel sujuv nii kõnes kui kirjas 
 jaapani keel arusaamine lihtsamast kõnest 
8. Teenistuskäik: 01.2014 – … aastaTartu Ülikool, keemik 
 
II Teaduslik ja arendustegevus 
1. Peamised uurimisvaldkonnad: 
LC/MS, metoodikate valideerimine, proovi eeltöötlus, pestitsiidid, HPLC, 
monoliitsed kolonnid 
 
2. Publikatsioonide loetelu: 
Anneli Kruve, Ivo Leito, Koit Herodes, Asko Laaniste, Rünno Lõhmus, 
Enhanced Nebulization Efficiency of Electrospray Mass Spectrometry: 
Improved Sensitivity and Detection Limit, J. Am. Soc. Mass Spectrom. 2012, 
23, 2051–2054 
Asko Laaniste, Anneli Kruve, Ivo Leito, Ensuring repeatability and robustness 
of poly(glycidyl methacrylate-co-ethylene dimethacrylate) HPLC monolithic 
columns of 3 mm id through covalent bonding to the column wall, J. Sep. 
Sci., 2013, 36, 2458–2463 
Asko Laaniste, Audrey Marechal, Racha El-Debs, Jerome Randon, Vincent 
Dugas, Claire Demesmay, “Thiol-ene” photoclick chemistry as a rapid and 
localizable functionalization pathway for silica capillary monolithic columns, 
J. Chromatogr. A, 2014, 1355, 296–300 
Audrey Marechal, Asko Laaniste, Racha El-Debs, Vincent Dugas, Claire 
Demesmay Versatile ene-thiol photoclick reaction for preparation of multi-
modal monolithic silica capillary columns, J. Chromatogr. A. 2014, 1365, 
140–147 
Jaanus Liigand, Anneli Kruve, Piia Liigand, Asko Laaniste, Marion Girod, 
Rodolphe Antoine, Ivo Leito, Transferability of the electrospray ionization 
efficiency scale between different instruments, J. Am. Soc. Mass Spectrom., 
2015, 26, 1923–30 
 147 
Asko Laaniste, Anneli Kruve, Ivo Leito, Riin Rebane, Rünno Lõhmus, Ants 
Lõhmus, Fredrik Punga, Determination of neonicotinoids in Estonian honey 
by LC/ESI/MS with novel nebulizer, Journal of Environmental Science and 
Health, Part B, accepted for publication. 
Asko Laaniste, Ivo Leito, Anneli Kruve, Comparison of different ionization 
sources for the LC/MS analysis of pesticides, submitted to Rapid Commu-
nications in Mass Spectrometry. 
 
3. Saadud uurimistoetused ja stipendiumid: 
2013  – Kristjan Jaagu osalise õppe stipendium teadustööks Lyonis, Prantsus-
maal. 
2014  –  Doktorikooli stipendium osalemaks 38.. ISEAC konverentsil. 
2015  –  Eesti Üliõpilaste Toetusfond USAs stipendium toetamaks finantsiliselt 
silmapaistvaid üliõpilasi. 
2015  –  Kristjan Jaagu stipendium osalemiseks HPLC 2016 konverentsil. 
 
4. Muu teaduslik organisatsiooniline ja erialane tegevus: 
ValChrom projekt “Development of software for validation of chromatographic 
methods” (registreerimisnumbriga 3.2.1201.13-0020) alamüksuse “Sup-
porting the development of R&D of info and communication technology” 
toetatud EU Regional Development Fund poolt. 
Roll projektis (10.2015 – end of project in 08.2015): valideerimisalase tark-
vara testimine ja arendamine vastavusse peamiste valideerimisjuhenditega 
(ICH, AOAC, EuraChem, IUPAC, EMA, FDA, NordVal); ValChrom 
tarkvara programmeerimine, ülevaade testimistest. 
 
III Õppetöö 
Analüütilise keemia praktikum I 
Alates 2007. aastast olen olnud teaduse populariseerija põhikooli ja gümnaa-
siumiastme õpilaste seas. Olen omanud juhtivat rolli “Teaduslaager” 2009–
2014 ja “Õpikojad” 2010–2016 väljatöötamisel ja läbiviimisel. 
Samuti olen Eesti keemiaolümpiaadi organiseeriva komitee liige alates 2012. 
aastast, viies läbi treeninglaagreid, koostades ülesandeid ning valmistades 
Eesti õpilasi ette rahvusvaheliseks olümpiaadiks. Lisaks võtan vabataht-
likuna osa Euroopa Teadusolümpiaadi EUSO 2016 organiseerimisest. 
 
IV Erialane enesetäiendus ja konverentsid 
30.11.2013 – Õppeassistentide koolitus, Tartu, Eesti. 
2013 – Tegin teadustööd Lyoni 1. Ülikoolis 5 kuud, prof. J. Randoni grupis, mis 
tegeleb monoliitsete kolonnide valmistamise ja funktrionaliseerimisega. 
11.10.2013. – Eesti XXXIII Keemiapäevad 
04.–05.03.2014. – TÜ ja TTÜ doktorikooli konverents “FMTDK Teaduskonve-
rents 2014”. 
16.–20.06.2014. – The 38th International Symposium on Environmental Analytical 
Chemistry 
 148 
Kevad 2015. – Mõõtemääramatuse hindamine keemilises analüüsis, Tartu, Eesti. 
21.06.2015. – SFC – Principles, Instrumentation, Method Development, and Appli-
cations, Genf, Šveits. 
21.–25.06.2015. – 42nd International Symposium on high performance liquid phase 
separations and related techniques (HPLC 2015). 
09.–10.06.2016. – 16th International Chromatography School, Zagreb. 
19.–24.06.2016. – 44  International Symposium on high performance liquid phase th
separations and related techniques (HPLC 2016), San Francisco, USA. 
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DISSERTATIONES CHIMICAE  
UNIVERSITATIS TARTUENSIS 
1. Toomas Tamm. Quantum-chemical simulation of solvent effects. Tartu, 
1993, 110 p. 
2. Peeter Burk. Theoretical study of gas-phase acid-base equilibria. Tartu, 
1994, 96 p. 
3. Victor Lobanov. Quantitative structure-property relationships in large 
descriptor spaces. Tartu, 1995, 135 p. 
4. Vahur Mäemets. The 17O and 1H nuclear magnetic resonance study of 
H2O in individual solvents and its charged clusters in aqueous solutions of 
electrolytes. Tartu, 1997, 140 p. 
5.  Andrus Metsala. Microcanonical rate constant in nonequilibrium distribu-
tion of vibrational energy and in restricted intramolecular vibrational 
energy redistribution on the basis of slater’s theory of unimolecular re-
actions. Tartu, 1997, 150 p. 
6. Uko Maran. Quantum-mechanical study of potential energy surfaces in 
different environments. Tartu, 1997, 137 p. 
7. Alar Jänes. Adsorption of organic compounds on antimony, bismuth and 
cadmium electrodes. Tartu, 1998, 219 p. 
8. Kaido Tammeveski. Oxygen electroreduction on thin platinum films and 
the electrochemical detection of superoxide anion. Tartu, 1998, 139 p. 
9. Ivo Leito. Studies of Brønsted acid-base equilibria in water and non-
aqueous media. Tartu, 1998, 101 p. 
10.  Jaan Leis. Conformational dynamics and equilibria in amides. Tartu, 1998, 
131 p. 
11.  Toonika Rinken. The modelling of amperometric biosensors based on oxi-
doreductases. Tartu, 2000, 108 p. 
12. Dmitri Panov. Partially solvated Grignard reagents. Tartu, 2000, 64 p.  
13. Kaja Orupõld. Treatment and analysis of phenolic wastewater with micro-
organisms. Tartu, 2000, 123 p. 
14. Jüri Ivask. Ion Chromatographic determination of major anions and 
cations in polar ice core. Tartu, 2000, 85 p. 
15. Lauri Vares. Stereoselective Synthesis of Tetrahydrofuran and Tetra-
hydropyran Derivatives by Use of Asymmetric Horner-Wadsworth- 
Emmons and Ring Closure Reactions. Tartu, 2000, 184 p.  
16. Martin Lepiku. Kinetic aspects of dopamine D2 receptor interactions with 
specific ligands. Tartu, 2000, 81 p. 
17. Katrin Sak. Some aspects of ligand specificity of P2Y receptors. Tartu, 
2000, 106 p. 
18. Vello Pällin. The role of solvation in the formation of iotsitch complexes. 
Tartu, 2001, 95 p. 
19.  Katrin Kollist. Interactions between polycyclic aromatic compounds and 
humic substances. Tartu, 2001, 93 p. 
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20. Ivar Koppel. Quantum chemical study of acidity of strong and superstrong 
Brønsted acids. Tartu, 2001, 104 p. 
21. Viljar Pihl. The study of the substituent and solvent effects on the acidity 
of OH and CH acids. Tartu, 2001, 132 p. 
22. Natalia Palm. Specification of the minimum, sufficient and significant set 
of descriptors for general description of solvent effects. Tartu, 2001, 134 p. 
23. Sulev Sild. QSPR/QSAR approaches for complex molecular systems. 
Tartu, 2001, 134 p. 
24. Ruslan Petrukhin. Industrial applications of the quantitative structure-
property relationships. Tartu, 2001, 162 p. 
25. Boris V. Rogovoy. Synthesis of (benzotriazolyl)carboximidamides and their 
application in relations with N- and S-nucleophyles. Tartu, 2002, 84 p. 
26. Koit Herodes. Solvent effects on UV-vis absorption spectra of some 
solvatochromic substances in binary solvent mixtures: the preferential 
solvation model. Tartu, 2002, 102 p. 
27. Anti Perkson. Synthesis and characterisation of nanostructured carbon. 
Tartu, 2002, 152 p. 
28. Ivari Kaljurand. Self-consistent acidity scales of neutral and cationic 
Brønsted acids in acetonitrile and tetrahydrofuran. Tartu, 2003, 108 p. 
29. Karmen Lust. Adsorption of anions on bismuth single crystal electrodes. 
Tartu, 2003, 128 p. 
30. Mare Piirsalu. Substituent, temperature and solvent effects on the alkaline 
hydrolysis of substituted phenyl and alkyl esters of benzoic acid. Tartu, 
2003, 156 p. 
31. Meeri Sassian. Reactions of partially solvated Grignard reagents. Tartu, 
2003, 78 p. 
32. Tarmo Tamm. Quantum chemical modelling of polypyrrole. Tartu, 2003. 
100 p. 
33. Erik Teinemaa. The environmental fate of the particulate matter and 
organic pollutants from an oil shale power plant. Tartu, 2003. 102 p. 
34. Jaana Tammiku-Taul. Quantum chemical study of the properties of 
Grignard reagents. Tartu, 2003. 120 p. 
35. Andre Lomaka. Biomedical applications of predictive computational  
chemistry. Tartu, 2003. 132 p. 
36. Kostyantyn Kirichenko. Benzotriazole – Mediated Carbon–Carbon Bond 
Formation. Tartu, 2003. 132 p. 
37. Gunnar Nurk. Adsorption kinetics of some organic compounds on bis-
muth single crystal electrodes. Tartu, 2003, 170 p. 
38. Mati Arulepp. Electrochemical characteristics of porous carbon materials 
and electrical double layer capacitors. Tartu, 2003, 196 p. 
39. Dan Cornel Fara. QSPR modeling of complexation and distribution of 
organic compounds. Tartu, 2004, 126 p. 
40. Riina Mahlapuu. Signalling of galanin and amyloid precursor protein 
through adenylate cyclase. Tartu, 2004, 124 p. 
151
41. Mihkel Kerikmäe. Some luminescent materials for dosimetric applications 
and physical research. Tartu, 2004, 143 p. 
42. Jaanus Kruusma. Determination of some important trace metal ions in 
human blood. Tartu, 2004, 115 p. 
43. Urmas Johanson. Investigations of the electrochemical properties of poly-
pyrrole modified electrodes. Tartu, 2004, 91 p. 
44. Kaido Sillar. Computational study of the acid sites in zeolite ZSM-5. 
Tartu, 2004, 80 p. 
45. Aldo Oras. Kinetic aspects of dATPαS interaction with P2Y1 receptor. 
Tartu, 2004, 75 p. 
46. Erik Mölder. Measurement of the oxygen mass transfer through the air-
water interface. Tartu, 2005, 73 p.  
47. Thomas Thomberg. The kinetics of electroreduction of peroxodisulfate 
anion on cadmium (0001) single crystal electrode. Tartu, 2005, 95 p. 
48. Olavi Loog. Aspects of condensations of carbonyl compounds and their 
imine analogues. Tartu, 2005, 83 p.  
49. Siim Salmar. Effect of ultrasound on ester hydrolysis in aqueous ethanol. 
Tartu, 2006, 73 p.  
50. Ain Uustare. Modulation of signal transduction of heptahelical receptors 
by other receptors and G proteins. Tartu, 2006, 121 p. 
51. Sergei Yurchenko. Determination of some carcinogenic contaminants in 
food. Tartu, 2006, 143 p.  
52. Kaido Tämm. QSPR modeling of some properties of organic compounds. 
Tartu, 2006, 67 p.  
53. Olga Tšubrik. New methods in the synthesis of multisubstituted hydra-
zines. Tartu. 2006, 183 p.  
54. Lilli Sooväli. Spectrophotometric measurements and their uncertainty in 
chemical analysis and dissociation constant measurements. Tartu, 2006,  
125 p. 
55. Eve Koort. Uncertainty estimation of potentiometrically measured ph and 
pKa values. Tartu, 2006, 139 p.  
56. Sergei Kopanchuk. Regulation of ligand binding to melanocortin receptor 
subtypes. Tartu, 2006, 119 p.  
57. Silvar Kallip. Surface structure of some bismuth and antimony single 
crystal electrodes. Tartu, 2006, 107 p. 
58. Kristjan Saal. Surface silanization and its application in biomolecule 
coupling. Tartu, 2006, 77 p. 
59. Tanel Tätte. High viscosity Sn(OBu)4 oligomeric concentrates and their 
applications in technology. Tartu, 2006, 91 p. 
60. Dimitar Atanasov Dobchev. Robust QSAR methods for the prediction of 
properties from molecular structure. Tartu, 2006, 118 p.  
61.  Hannes Hagu. Impact of ultrasound on hydrophobic interactions in 
solutions. Tartu, 2007, 81 p. 
152
62. Rutha Jäger. Electroreduction of peroxodisulfate anion on bismuth 
electrodes. Tartu, 2007, 142 p. 
63. Kaido Viht. Immobilizable bisubstrate-analogue inhibitors of basophilic 
protein kinases: development and application in biosensors. Tartu, 2007,  
88 p. 
64. Eva-Ingrid Rõõm. Acid-base equilibria in nonpolar media. Tartu, 2007, 
156 p. 
65. Sven Tamp. DFT study of the cesium cation containing complexes relevant 
to the cesium cation binding by the humic acids. Tartu, 2007, 102 p. 
66. Jaak Nerut. Electroreduction of hexacyanoferrate(III) anion on Cadmium 
(0001) single crystal electrode. Tartu, 2007, 180 p.  
67. Lauri Jalukse. Measurement uncertainty estimation in amperometric 
dissolved oxygen concentration measurement. Tartu, 2007, 112 p. 
68. Aime Lust. Charge state of dopants and ordered clusters formation in 
CaF2:Mn and CaF2:Eu luminophors. Tartu, 2007, 100 p. 
69. Iiris Kahn. Quantitative Structure-Activity Relationships of environ-
mentally relevant properties. Tartu, 2007, 98 p. 
70. Mari Reinik. Nitrates, nitrites, N-nitrosamines and polycyclic aromatic 
hydrocarbons in food: analytical methods, occurrence and dietary intake. 
Tartu, 2007, 172 p. 
71. Heili Kasuk. Thermodynamic parameters and adsorption kinetics of orga-
nic compounds forming the compact adsorption layer at Bi single crystal 
electrodes. Tartu, 2007, 212 p. 
72. Erki Enkvist. Synthesis of adenosine-peptide conjugates for biological 
applications. Tartu, 2007, 114 p.  
73. Svetoslav Hristov Slavov. Biomedical applications of the QSAR approach. 
Tartu, 2007, 146 p. 
74. Eneli Härk. Electroreduction of complex cations on electrochemically 
polished Bi(hkl) single crystal electrodes. Tartu, 2008, 158 p.  
75. Priit Möller. Electrochemical characteristics of some cathodes for medium 
temperature solid oxide fuel cells, synthesized by solid state reaction 
technique. Tartu, 2008, 90 p.  
76. Signe Viggor. Impact of biochemical parameters of genetically different 
pseudomonads at the degradation of phenolic compounds. Tartu, 2008, 122 p. 
77. Ave Sarapuu. Electrochemical reduction of oxygen on quinone-modified 
carbon electrodes and on thin films of platinum and gold. Tartu, 2008,  
134 p.  
78. Agnes Kütt. Studies of acid-base equilibria in non-aqueous media. Tartu, 
2008, 198 p.  
79. Rouvim Kadis. Evaluation of measurement uncertainty in analytical che-
mistry: related concepts and some points of misinterpretation. Tartu, 2008, 
118 p. 
80.  Valter Reedo. Elaboration of IVB group metal oxide structures and their 
possible applications. Tartu, 2008, 98 p. 
153 
81.  Aleksei Kuznetsov. Allosteric effects in reactions catalyzed by the cAMP-
dependent protein kinase catalytic subunit. Tartu, 2009, 133 p. 
82. Aleksei Bredihhin. Use of mono- and polyanions in the synthesis of 
multisubstituted hydrazine derivatives. Tartu, 2009, 105 p. 
83. Anu Ploom. Quantitative structure-reactivity analysis in organosilicon 
chemistry. Tartu, 2009, 99 p.  
84. Argo Vonk. Determination of adenosine A2A- and dopamine D1 receptor-
specific modulation of adenylate cyclase activity in rat striatum. Tartu, 
2009, 129 p. 
85.  Indrek Kivi. Synthesis and electrochemical characterization of porous 
cathode materials for intermediate temperature solid oxide fuel cells. Tartu, 
2009, 177 p.  
86. Jaanus Eskusson. Synthesis and characterisation of diamond-like carbon 
thin films prepared by pulsed laser deposition method. Tartu, 2009, 117 p. 
87. Marko Lätt. Carbide derived microporous carbon and electrical double 
layer capacitors. Tartu, 2009, 107 p. 
88. Vladimir Stepanov. Slow conformational changes in dopamine transporter 
interaction with its ligands. Tartu, 2009, 103 p.  
89. Aleksander Trummal. Computational Study of Structural and Solvent 
Effects on Acidities of Some Brønsted Acids. Tartu, 2009, 103 p. 
90.  Eerold Vellemäe. Applications of mischmetal in organic synthesis. Tartu, 
2009, 93 p. 
91.  Sven Parkel. Ligand binding to 5-HT1A receptors and its regulation by 
Mg2+ and Mn2+. Tartu, 2010, 99 p. 
92.  Signe Vahur. Expanding the possibilities of ATR-FT-IR spectroscopy in 
determination of inorganic pigments. Tartu, 2010, 184 p. 
93. Tavo Romann. Preparation and surface modification of bismuth thin film, 
porous, and microelectrodes. Tartu, 2010, 155 p. 
94. Nadežda Aleksejeva. Electrocatalytic reduction of oxygen on carbon 
nanotube-based nanocomposite materials. Tartu, 2010, 147 p.  
95.  Marko Kullapere. Electrochemical properties of glassy carbon, nickel and 
gold electrodes modified with aryl groups. Tartu, 2010, 233 p. 
96. Liis Siinor. Adsorption kinetics of ions at Bi single crystal planes from 
aqueous electrolyte solutions and room-temperature ionic liquids. Tartu, 
2010, 101 p. 
97.   Angela Vaasa. Development of fluorescence-based kinetic and binding 
assays for characterization of protein kinases and their inhibitors. Tartu 
2010, 101 p. 
98. Indrek Tulp. Multivariate analysis of chemical and biological properties. 
Tartu 2010, 105 p. 
99.  Aare Selberg. Evaluation of environmental quality in Northern Estonia by 
the analysis of leachate. Tartu 2010, 117 p. 
100. Darja Lavõgina. Development of protein kinase inhibitors based on 
adenosine analogue-oligoarginine conjugates. Tartu 2010, 248 p. 
154
101. Laura Herm. Biochemistry of dopamine D2 receptors and its association 
with motivated behaviour. Tartu 2010, 156 p. 
102. Terje Raudsepp. Influence of dopant anions on the electrochemical pro-
perties of polypyrrole films. Tartu 2010, 112 p.  
103.  Margus Marandi. Electroformation of Polypyrrole Films: In-situ AFM 
and STM Study. Tartu 2011, 116 p. 
104. Kairi Kivirand. Diamine oxidase-based biosensors: construction and 
working principles. Tartu, 2011, 140 p. 
105. Anneli Kruve. Matrix effects in liquid-chromatography electrospray mass-
spectrometry. Tartu, 2011, 156 p. 
106. Gary Urb. Assessment of environmental impact of oil shale fly ash from 
PF and CFB combustion.  Tartu, 2011, 108 p. 
107. Nikita Oskolkov. A novel strategy for peptide-mediated cellular delivery 
and induction of endosomal escape. Tartu, 2011, 106 p. 
108. Dana Martin. The QSPR/QSAR approach for the prediction of properties of 
fullerene derivatives. Tartu, 2011, 98 p. 
109.  Säde Viirlaid. Novel glutathione analogues and their antioxidant activity. 
Tartu, 2011, 106 p. 
110.  Ülis Sõukand. Simultaneous adsorption of Cd2+, Ni2+, and Pb2+ on peat. 
Tartu, 2011, 124 p. 
111. Lauri Lipping. The acidity of strong and superstrong Brønsted acids, an 
outreach for the “limits of growth”: a quantum chemical study. Tartu, 
2011, 124 p. 
112. Heisi Kurig. Electrical double-layer capacitors based on ionic liquids as 
electrolytes. Tartu, 2011, 146 p. 
113. Marje Kasari. Bisubstrate luminescent probes, optical sensors and affinity 
adsorbents for measurement of active protein kinases in biological 
samples. Tartu, 2012, 126 p. 
114. Kalev Takkis. Virtual screening of chemical databases for bioactive mole-
cules. Tartu, 2012, 122 p. 
115. Ksenija Kisseljova. Synthesis of aza-β3-amino acid containing peptides 
and kinetic study of their phosphorylation by protein kinase A. Tartu, 
2012, 104 p. 
116. Riin Rebane. Advanced method development strategy for derivatization 
LC/ESI/MS. Tartu, 2012, 184 p. 
117. Vladislav Ivaništšev. Double layer structure and adsorption kinetics of 
ions at metal electrodes in room temperature ionic liquids. Tartu, 2012, 
128 p. 
118.  Irja Helm. High accuracy gravimetric Winkler method for determination 
of dissolved oxygen. Tartu, 2012, 139 p. 
119. Karin Kipper. Fluoroalcohols as Components of LC-ESI-MS Eluents: 
Usage and Applications. Tartu, 2012, 164 p. 
120. Arno Ratas. Energy storage and transfer in dosimetric luminescent 
materials. Tartu, 2012, 163 p. 
121.  Reet Reinart-Okugbeni. Assay systems for characterisation of subtype-
selective binding and functional activity of ligands on dopamine recep-
tors. Tartu, 2012, 159 p. 
122.  Lauri Sikk. Computational study of the Sonogashira cross-coupling 
reaction. Tartu, 2012, 81 p. 
123. Karita Raudkivi. Neurochemical studies on inter-individual differences 
in affect-related behaviour of the laboratory rat. Tartu, 2012, 161 p. 
124.  Indrek Saar. Design of GalR2 subtype specific ligands: their role in 
depression-like behavior and feeding regulation. Tartu, 2013, 126 p. 
125. Ann Laheäär. Electrochemical characterization of alkali metal salt based 
non-aqueous electrolytes for supercapacitors. Tartu, 2013, 127 p.  
126.  Kerli Tõnurist. Influence of electrospun separator materials properties on 
electrochemical performance of electrical double-layer capacitors. Tartu, 
2013, 147 p. 
127.  Kaija Põhako-Esko. Novel organic and inorganic ionogels: preparation 
and characterization. Tartu, 2013, 124 p.  
128.  Ivar Kruusenberg. Electroreduction of oxygen on carbon nanomaterial-
based catalysts. Tartu, 2013, 191 p. 
129. Sander Piiskop. Kinetic effects of ultrasound in aqueous acetonitrile 
solutions. Tartu, 2013, 95 p. 
130.  Ilona Faustova. Regulatory role of L-type pyruvate kinase N-terminal 
domain. Tartu, 2013, 109 p. 
131. Kadi Tamm. Synthesis and characterization of the micro-mesoporous 
anode materials and testing of the medium temperature solid oxide fuel 
cell single cells. Tartu, 2013, 138 p.  
132.  Iva Bozhidarova Stoyanova-Slavova. Validation of QSAR/QSPR for 
regulatory purposes. Tartu, 2013, 109 p. 
133. Vitali Grozovski. Adsorption of organic molecules at single crystal 
electrodes studied by in situ STM method. Tartu, 2014, 146 p. 
134. Santa Veikšina. Development of assay systems for characterisation of 
ligand binding properties to melanocortin 4 receptors. Tartu, 2014, 151 p. 
135. Jüri Liiv. PVDF (polyvinylidene difluoride) as material for active 
element  of twisting-ball displays. Tartu, 2014, 111 p. 
136. Kersti Vaarmets. Electrochemical and physical characterization of 
pristine and activated molybdenum carbide-derived carbon electrodes for 
the oxygen electroreduction reaction. Tartu, 2014, 131 p. 
137. Lauri Tõntson. Regulation of G-protein subtypes by receptors, guanine 
nucleotides and Mn2+. Tartu, 2014, 105 p. 
138. Aiko Adamson. Properties of amine-boranes and phosphorus analogues 
in the gas phase. Tartu, 2014, 78 p. 
139. Elo Kibena. Electrochemical grafting of glassy carbon, gold, highly 
oriented pyrolytic graphite and chemical vapour deposition-grown graphene 
electrodes by diazonium reduction method. Tartu, 2014, 184 p.  
155
140.  Teemu Näykki. Novel Tools for Water Quality Monitoring – From Field 
to Laboratory. Tartu, 2014, 202 p. 
141.  Karl Kaupmees. Acidity and basicity in non-aqueous media: importance 
of solvent properties and purity. Tartu, 2014, 128 p. 
142. Oleg Lebedev. Hydrazine polyanions: different strategies in the synthesis 
of heterocycles. Tartu, 2015, 118 p. 
143.  Geven Piir. Environmental risk assessment of chemicals using QSAR 
methods. Tartu, 2015, 123 p. 
144.   Olga Mazina. Development and application of the biosensor assay for 
measurements of cyclic adenosine monophosphate in studies of G protein-
coupled receptor signalinga. Tartu, 2015, 116 p. 
145.  Sandip Ashokrao Kadam. Anion receptors: synthesis and accurate 
binding measurements. Tartu, 2015, 116 p. 
146.  Indrek Tallo. Synthesis and characterization of new micro-mesoporous 
carbide derived carbon materials for high energy and power density 
electrical double layer capacitors. Tartu, 2015, 148 p. 
147.  Heiki Erikson. Electrochemical reduction of oxygen on nanostructured 
palladium and gold catalysts. Tartu, 2015, 204 p. 
148.  Erik Anderson. In situ Scanning Tunnelling Microscopy studies of the 
interfacial structure between Bi(111) electrode and a room temperature 
ionic liquid. Tartu, 2015, 118 p. 
149.  Girinath G. Pillai. Computational Modelling of Diverse Chemical, Bio-
chemical and Biomedical Properties. Tartu, 2015, 140 p. 
150. Piret Pikma. Interfacial structure and adsorption of organic compounds at 
Cd(0001) and Sb(111) electrodes from ionic liquid and aqueous 
electrolytes: an in situ STM study. Tartu, 2015, 126 p. 
151. Ganesh babu Manoharan. Combining chemical and genetic approaches 
for photoluminescence assays of protein kinases. Tartu, 2016, 126 p. 
152. Carolin Siimenson. Electrochemical characterization of halide ion 
adsorption from liquid mixtures at Bi(111) and pyrolytic graphite 
electrode surface. Tartu, 2016,   110 p.
